

# Lead Times and Overdetection Due to Prostate-Specific Antigen Testing in the European Randomized Study of Screening for Prostate Cancer

Journal of the National Cancer Institute

95, 868-878

DOI: [10.1093/jnci/95.12.868](https://doi.org/10.1093/jnci/95.12.868)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Editorial: Priorities in future research in prostate cancer screening. <i>European Journal of Epidemiology</i> , 2002, 18, 1021-1024.	2.5	3
2	Why improvement in survival of screen-detected cases is not necessarily equivalent to benefit?. <i>Breast</i> , 2003, 12, 299-301.	0.9	3
3	The story of the European Randomized Study of Screening for Prostate Cancer. <i>BJU International</i> , 2003, 92, 1-13.	1.3	147
4	MISCAN: estimating lead-time and over-detection by simulation. <i>BJU International</i> , 2003, 92, 106-111.	1.3	24
5	Monitoring the ERSPC trial. <i>BJU International</i> , 2003, 92, 112-114.	1.3	15
6	European Randomized Study of Screening for Prostate Cancer: achievements and presentation. <i>BJU International</i> , 2003, 92, 117-122.	1.3	58
7	Trends in prostate cancer mortality among black men and white men in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 483-484.	0.8	1
8	Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 484-485.	0.8	0
9	Cancer Trends in the United States--A View From Europe. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1258-1261.	3.0	27
10	Interval Carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1462-1466.	3.0	55
11	Simulated Screening for Prostate Cancer: the Useful Model. <i>Journal of the National Cancer Institute</i> , 2003, 95, 838-839.	3.0	5
12	Free to Total Psa Ratio is not a Reliable Predictor of Prostate Biopsy Outcome. <i>Tumori</i> , 2004, 90, 324-327.	0.6	6
14	The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing. <i>Statistical Methods in Medical Research</i> , 2004, 13, 421-442.	0.7	39
15	Improved Biomarkers for Prostate Cancer: A Definite Need. <i>Journal of the National Cancer Institute</i> , 2004, 96, 813-815.	3.0	24
16	Phosphorylation of Akt (Ser473) is an Excellent Predictor of Poor Clinical Outcome in Prostate Cancer. <i>Cancer Research</i> , 2004, 64, 5232-5236.	0.4	311
17	Quantitative Pathology in Tissue MR Spectroscopy Based Human Prostate Metabolomics. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 591-598.	0.8	45
18	Combining longitudinal studies of PSA. <i>Biostatistics</i> , 2004, 5, 483-500.	0.9	32
19	An Ecologic Study of Prostate-specific Antigen Screening and Prostate Cancer Mortality in Nine Geographic Areas of the United States. <i>American Journal of Epidemiology</i> , 2004, 160, 1059-1069.	1.6	36

#	ARTICLE	IF	CITATIONS
20	An Early and Late Stage Convolution Model for Disease Natural History. <i>Biometrics</i> , 2004, 60, 191-198.	0.8	17
21	Active surveillance of early prostate cancer: rationale, initial results and future developments. <i>Prostate Cancer and Prostatic Diseases</i> , 2004, 7, 184-187.	2.0	28
22	Prostate Volume Ultrasonography: The Influence of Transabdominal versus Transrectal Approach, Device Type and Operator. <i>European Urology</i> , 2004, 46, 352-356.	0.9	41
23	Molecular Biomarker in Prostate Cancer: The Role of CpG Island Hypermethylation. <i>European Urology</i> , 2004, 46, 698-708.	0.9	107
24	Clinical Consequences of Screening for Prostate Cancer: 15 Years Follow-up of a Randomised Controlled Trial in Sweden. <i>European Urology</i> , 2004, 46, 717-724.	0.9	73
25	PSA-Test zur Früherkennung des Prostatakarzinoms. <i>Onkologie</i> , 2004, 10, 66-74.	0.7	3
26	Recent increase in cancer survival according to age: higher survival in all age groups, but widening age gradient. <i>Cancer Causes and Control</i> , 2004, 15, 903-910.	0.8	31
27	Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. <i>Cancer</i> , 2004, 100, 968-975.	2.0	19
28	Characteristics of insignificant clinical T1c prostate tumors. <i>Cancer</i> , 2004, 101, 2001-2005.	2.0	213
29	Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. <i>International Journal of Cancer</i> , 2004, 111, 940-943.	2.3	23
30	Comparison of the prognostic potential of hyaluronic acid, hyaluronidase(HYAL-1), CD44v6 and microvessel density for prostate cancer. <i>International Journal of Cancer</i> , 2004, 112, 121-129.	2.3	85
31	Costs and effects of prostate cancer screening in Sweden A 15-year follow-up of a randomized trial. <i>Scandinavian Journal of Urology and Nephrology</i> , 2004, 38, 291-298.	1.4	22
33	Prostate-specific antigen and screening for prostate cancer. <i>Medical Clinics of North America</i> , 2004, 88, 245-265.	1.1	16
34	THE RELATIVE IMPACT AND FUTURE BURDEN OF PROSTATE CANCER IN THE UNITED STATES. <i>Journal of Urology</i> , 2004, 172, .	0.2	160
35	PROSTATE CANCER CHARACTERISTICS AND PROSTATE SPECIFIC ANTIGEN CHANGES IN SCREENING DETECTED PATIENTS INITIALLY TREATED WITH A WATCHFUL WAITING POLICY. <i>Journal of Urology</i> , 2004, 172, 2193-2196.	0.2	21
36	Screening for prostate cancer: current recommendations. <i>Urologic Clinics of North America</i> , 2004, 31, 219-226.	0.8	31
39	No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam). <i>Urology</i> , 2004, 63, 892-897.	0.5	16
40	Continued undertreatment of older men with localized prostate cancer. <i>Urology</i> , 2004, 64, 189-190.	0.5	1

#	ARTICLE	IF	CITATIONS
41	Time trends in pathologic features of radical prostatectomy—impact of family history. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 169-173.	0.8	7
42	Reducing PSA Anxiety: The importance of noninvasive chronic disease management in prostate cancer detection and treatment. <i>American Journal of Medicine</i> , 2004, 117, 796-798.	0.6	4
43	Active surveillance: towards a new paradigm in the management of early prostate cancer. <i>Lancet Oncology</i> , The, 2004, 5, 101-106.	5.1	176
44	A Nested Case-Control Study of Prostate Cancer and Atrazine Exposure. <i>Journal of Occupational and Environmental Medicine</i> , 2004, 46, 379-385.	0.9	29
46	Update on screening and early detection of prostate cancer. <i>Current Opinion in Urology</i> , 2004, 14, 151-156.	0.9	7
47	Knowledge of the Limitations Associated With Prostate Cancer Screening Among Low-income Men. <i>Cancer Nursing</i> , 2004, 27, 442-451.	0.7	44
50	Prostate-specific Antigen Testing in Healthy Men: A UK Perspective. <i>Clinical Oncology</i> , 2005, 17, 228-230.	0.6	3
52	Part 1: The burden of prostate cancer, its natural history, information on the outcome of screening and estimates of ad hoc screening with particular reference to England and Wales. <i>BJU International</i> , 2005, 95, 4-15.	1.3	26
53	The Scandinavian prostate cancer group study: the case for conservative management. <i>BJU International</i> , 2005, 96, 952-953.	1.3	2
54	PSA Updated: Still Relevant in the New Millennium?. <i>European Urology</i> , 2005, 47, 427-432.	0.9	27
55	Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of $\geq 10$ ng/ml: Systematic Review and Meta-Analysis. <i>European Urology</i> , 2005, 48, 386-399.	0.9	222
56	Micro-Focal Prostate Cancer: A Comparison of Biopsy and Radical Prostatectomy Specimen Features. <i>European Urology</i> , 2005, 48, 895-899.	0.9	79
57	Does the Tertiary Gleason Pattern Influence the PSA Progression-Free Interval after Retropubic Radical Prostatectomy for Organ-Confined Prostate Cancer?. <i>European Urology</i> , 2005, 48, 572-576.	0.9	47
58	The PSA Era is not Over for Prostate Cancer. <i>European Urology</i> , 2005, 48, 541-545.	0.9	52
59	Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. <i>International Journal of Cancer</i> , 2005, 116, 291-296.	2.3	158
60	Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. <i>Cancer</i> , 2005, 103, 708-716.	2.0	30
61	Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?. <i>Acta Oncologica</i> , 2005, 44, 255-264.	0.8	23
62	The Changing Face of Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8146-8151.	0.8	293

#	ARTICLE	IF	CITATIONS
63	Long-Term Survival Rates of Patients With Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period Analysis. <i>Journal of Clinical Oncology</i> , 2005, 23, 441-447.	0.8	73
64	Serum Antibodies to Huntingtin Interacting Protein-1: A New Blood Test for Prostate Cancer. <i>Cancer Research</i> , 2005, 65, 4126-4133.	0.4	54
65	Total and Percent Free Prostate-Specific Antigen Levels among U.S. Men, 2001-2002. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2178-2182.	1.1	29
66	What is the value of screening for prostate cancer in the US?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 536-537.	4.3	13
67	Does current evidence justify prostate cancer screening in Europe?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 538-539.	4.3	10
68	Prognostic value of serum markers for prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 64-81.	1.4	63
69	Watchful Waiting, Temporarily Deferred Therapy, or Active Surveillance?. <i>Journal of Clinical Oncology</i> , 2005, 23, 1322-1322.	0.8	1
70	Prostate cancer: screening approaches. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005, 66, 623-626.	0.2	3
71	20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2095.	3.8	1,027
72	Period Analysis of Prostate Cancer Survival. <i>Journal of Clinical Oncology</i> , 2005, 23, 407-409.	0.8	5
73	Rising prostate specific antigen (PSA) during follow-up of prostate cancer patients â€” what to do?. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 309-315.	2.2	0
74	COMPARISON OF SCREEN DETECTED AND CLINICALLY DIAGNOSED PROSTATE CANCER IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, SECTION ROTTERDAM. <i>Journal of Urology</i> , 2005, 174, 121-125.	0.2	68
75	USE OF 2.6 NG/ML PROSTATE SPECIFIC ANTIGEN PROMPT FOR BIOPSY IN MEN OLDER THAN 60 YEARS. <i>Journal of Urology</i> , 2005, 174, 2154-2157.	0.2	49
76	4-YEAR PROSTATE SPECIFIC ANTIGEN PROGRESSION AND DIAGNOSIS OF PROSTATE CANCER IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, SECTION ROTTERDAM. <i>Journal of Urology</i> , 2005, 174, 489-494.	0.2	47
77	Prostate Cancer and the Will Rogers Phenomenon. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1248-1253.	3.0	369
78	Life expectancy and the value of early detection. <i>Journal of Health Economics</i> , 2005, 24, 891-906.	1.3	40
79	Radical prostatectomy for early prostate cancer improves long term survival. <i>Cancer Treatment Reviews</i> , 2005, 31, 640-643.	3.4	4
80	Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991â€“1994). <i>European Journal of Cancer</i> , 2005, 41, 411-415.	1.3	32

#	ARTICLE	IF	CITATIONS
81	Screening for prostate cancer. <i>European Journal of Cancer</i> , 2005, 41, 825-833.	1.3	71
82	Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). <i>Urology</i> , 2005, 65, 343-346.	0.5	70
83	Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: Review of 36,316 biopsies. <i>Urology</i> , 2005, 65, 549-553.	0.5	64
84	Additional use of [ <sup>18</sup> F] precursor prostate-specific antigen and <sup>18</sup> F-benign-PSA at diagnosis in screen-detected prostate cancer. <i>Urology</i> , 2005, 65, 926-930.	0.5	23
85	Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages. <i>Urology</i> , 2005, 66, 1038-1042.	0.5	22
87	COMPARISON OF THE INCIDENCE OF LATENT PROSTATE CANCER DETECTED AT AUTOPSY BEFORE AND AFTER THE PROSTATE SPECIFIC ANTIGEN ERA. <i>Journal of Urology</i> , 2005, 174, 1785-1788.	0.2	85
88	THE INDEPENDENT IMPACT OF EXTENDED PATTERN BIOPSY ON PROSTATE CANCER STAGE MIGRATION. <i>Journal of Urology</i> , 2005, 174, 1789-1793.	0.2	55
89	EARLY STAGE PROSTATE CANCER—DO WE HAVE A PROBLEM WITH OVER-DETECTION, OVERTREATMENT OR BOTH?. <i>Journal of Urology</i> , 2005, 173, 1061-1062.	0.2	106
90	DELAYS IN CANCER DETECTION USING 2 AND 4-YEAR SCREENING INTERVALS FOR PROSTATE CANCER SCREENING WITH INITIAL PROSTATE SPECIFIC ANTIGEN LESS THAN 2 NG/ML. <i>Journal of Urology</i> , 2005, 173, 1116-1120.	0.2	14
91	Overdiagnosis and breast cancer screening. <i>Breast Cancer Research</i> , 2005, 7, 228-9.	2.2	28
92	Active Surveillance with Selective Delayed Intervention for Favourable Risk Prostate Cancer: Clinical Experience and a <sup>18</sup> F-Number Needed to Treat Analysis. <i>European Urology Supplements</i> , 2006, 5, 479-486.	0.1	12
93	The Case for Prostate Cancer Screening with Prostate-Specific Antigen. <i>European Urology Supplements</i> , 2006, 5, 737-745.	0.1	6
96	Prognostic Markers Under Watchful Waiting and Radical Prostatectomy. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 845-855.	0.9	29
97	Decision Making in Prostate-Specific Antigen Screening. <i>American Journal of Preventive Medicine</i> , 2006, 30, 394-404.	1.6	46
100	PSA and the Detection of Prostate Cancer After 2005. Part I. <i>EAU-EBU Update Series</i> , 2006, 4, 2-12.	0.7	7
101	PSA and the Detection of Prostate Cancer After 2005. Part II: Ways Out of the PSA Dilemma?. <i>EAU-EBU Update Series</i> , 2006, 4, 71-81.	0.7	2
102	Prostate cancer diagnosis: The impact on patients' mental health. <i>European Journal of Cancer</i> , 2006, 42, 165-170.	1.3	37
103	Prostate cancer specific mortality in the Florence screening pilot study cohort 1992-1993. <i>European Journal of Cancer</i> , 2006, 42, 1858-1862.	1.3	8

#	ARTICLE	IF	CITATIONS
104	Free and total human glandular kallikrein 2 in patients with prostate cancer. <i>Urology</i> , 2006, 68, 219-225.	0.5	8
105	Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. <i>Urology</i> , 2006, 68, 342-347.	0.5	40
106	Expectant treatment with curative intent in the prostate-specific antigen era: Triggers for definitive therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 51-57.	0.8	21
107	Single nucleotide polymorphisms: Early diagnosis and risk assessment in genitourinary malignancy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 224-230.	0.8	0
108	Modeling the Effect of a Preventive Intervention on the Natural History of Cancer: Application to the Prostate Cancer Prevention Trial. <i>International Journal of Biostatistics</i> , 2006, 2, .	0.4	1
109	On the Clinical Usefulness of the Free-to-Total Prostate-Specific Antigen Ratio. <i>International Journal of Biological Markers</i> , 2006, 21, 1-5.	0.7	2
110	PSA Screening Among Elderly Men With Limited Life Expectancies. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2336.	3.8	235
111	The Role of Prevalence in the Diagnosis of Prostate Cancer. <i>Cancer Control</i> , 2006, 13, 158-168.	0.7	73
112	Viewpoint: Limiting Prostate Cancer Screening. <i>Annals of Internal Medicine</i> , 2006, 144, 438.	2.0	32
113	A population model of prostate cancer incidence. <i>Statistics in Medicine</i> , 2006, 25, 2846-2866.	0.8	47
114	Establishing normal reference ranges for PSA change with age in a population-based study: The Krimpen study. <i>Prostate</i> , 2006, 66, 335-343.	1.2	23
115	Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. <i>Prostate</i> , 2006, 66, 49-56.	1.2	44
116	A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55â€“75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC,) Tj ETQq0 0 0 ngB /Overck 10 Tf	1.2	45
117	Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). <i>Prostate</i> , 2006, 66, 1076-1081.	1.2	11
118	Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia. <i>British Journal of Cancer</i> , 2006, 95, 401-405.	2.9	35
119	Shift of tumor features in patients with clinically localized prostate cancer undergoing radical prostatectomy since the beginning of the PSA era. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 348-354.	1.0	4
120	Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening?. <i>Current Treatment Options in Oncology</i> , 2006, 7, 337-345.	1.3	27
121	Tumour Features in the Control and Screening Arm of A Randomized Trial of Prostate Cancer. <i>European Urology</i> , 2006, 50, 70-75.	0.9	35

#	ARTICLE	IF	CITATIONS
122	Extent of Prostate-Specific Antigen Contamination in the Spanish Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). <i>European Urology</i> , 2006, 50, 1234-1240.	0.9	23
123	Management and Survival of Screen-Detected Prostate Cancer Patients who Might Have Been Suitable for Active Surveillance. <i>European Urology</i> , 2006, 50, 475-482.	0.9	67
124	The Motion: There is Evidence That Prostate Cancer Screening Does More Good Than Harm. <i>European Urology</i> , 2006, 50, 377-380.	0.9	2
125	For the motion. <i>European Urology</i> , 2006, 50, 377-379.	0.9	10
126	Patients'™ perceptions of the side-effects of prostate cancer treatment"™A qualitative interview study. <i>Social Science and Medicine</i> , 2006, 63, 911-919.	1.8	75
127	Metastatic disease of screen-detected prostate cancer. <i>Cancer</i> , 2006, 107, 2779-2785.	2.0	3
128	Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer. <i>International Journal of Cancer</i> , 2006, 118, 2538-2542.	2.3	12
129	Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence. <i>International Journal of Cancer</i> , 2006, 119, 1082-1087.	2.3	71
130	Gleason score, age and screening: Modeling dedifferentiation in prostate cancer. <i>International Journal of Cancer</i> , 2006, 119, 2366-2371.	2.3	70
131	Screening for prostate cancer. , 2006, , CD004720.		74
132	Prostate cancer: risks and benefits of screening. <i>Nature Reviews Urology</i> , 2006, 3, 4-5.	1.4	1
133	Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. <i>Acta Oncol"³gica</i> , 2006, 45, 454-462.	0.8	7
134	Chapter 9: The MISCAN-Fadia Continuous Tumor Growth Model for Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2006, 2006, 56-65.	0.9	74
135	Comparison of Observed and Expected Numbers of Detected Cancers in the Research Center for Cancer Prevention and Screening Program. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 301-308.	0.6	33
136	Risk of Cardiovascular Mortality in Prostate Cancer Patients in the Rotterdam Randomized Screening Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 4184-4189.	0.8	15
137	Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1134-1141.	3.0	209
138	PSA Testing. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2371.	3.8	14
139	Assessing Risk: Does This Patient Have Prostate Cancer?. <i>Journal of the National Cancer Institute</i> , 2006, 98, 506-507.	3.0	15

#	ARTICLE	IF	CITATIONS
140	Androgen Induction of Prostate Cancer Cell Invasion Is Mediated by Ezrin. <i>Journal of Biological Chemistry</i> , 2006, 281, 29938-29948.	1.6	68
141	Metabolic Syndrome Predicts Prostate Cancer in a Cohort of Middle-aged Norwegian Men Followed for 27 Years. <i>American Journal of Epidemiology</i> , 2006, 164, 769-774.	1.6	154
142	Biomarkers and screening for prostate cancer. <i>Annals of Oncology</i> , 2006, 17, x200-x206.	0.6	3
143	Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1521-1527.	3.0	287
144	Delayed Versus Immediate Surgical Intervention and Prostate Cancer Outcome. <i>Journal of the National Cancer Institute</i> , 2006, 98, 355-357.	3.0	200
145	A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. <i>British Journal of Cancer</i> , 2006, 94, 1361-1368.	2.9	131
146	A model of the natural history of screen-detected prostate cancer. <i>British Journal of Cancer</i> , 2006, 95, 1122-1123.	2.9	4
147	PSA level changes over time in men with an initial PSA level of $\leq 4$ ng/ml. <i>Nature Reviews Urology</i> , 2006, 3, 520-521.	1.4	0
148	Use of Modeling to Evaluate the Cost-Effectiveness of Cancer Screening Programs. <i>Journal of Clinical Oncology</i> , 2007, 25, 203-208.	0.8	47
149	Will focal therapy become a standard of care for men with localized prostate cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 632-642.	4.3	148
150	How common is PSA screening in elderly men with limited life expectancies?. <i>Nature Reviews Urology</i> , 2007, 4, 532-533.	1.4	1
151	Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2007, 18, ii36-ii37.	0.6	6
152	Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 763-774.	0.6	0
153	Commentary: Implications of the frequent occurrence of occult carcinoma of the prostate. <i>International Journal of Epidemiology</i> , 2007, 36, 282-284.	0.9	11
154	Interval Cancers in Prostate Cancer Screening: Comparing 2- and 4-Year Screening Intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1296-1303.	3.0	61
155	Interpreting Trends in Prostate Cancer Incidence and Mortality in the Five Nordic Countries. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1881-1887.	3.0	157
156	Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years. <i>Journal of Clinical Oncology</i> , 2007, 25, 431-436.	0.8	187
157	Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1510-1515.	3.0	52

#	ARTICLE	IF	CITATIONS
158	Critical Review: Is Watchful Waiting a Viable Management Option for Older Men With Prostate Cancer?. American Journal of Men's Health, 2007, 1, 18-28.	0.7	5
159	Commentary: Occult prostate cancer—imposter or the real deal?. International Journal of Epidemiology, 2007, 36, 281-282.	0.9	4
160	Prostate cancer: the new evidence base for diagnosis and treatment. Pathology, 2007, 39, 537-544.	0.3	14
161	Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. BMJ: British Medical Journal, 2007, 335, 1139.	2.4	18
162	Active Surveillance With Selective Radical Treatment for Localized Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2007, 13, 289-294.	1.0	45
163	Prostate-Specific Antigen Velocity Risk Count Assessment: A New Concept for Detection of Life-Threatening Prostate Cancer During Window of Curability. Urology, 2007, 70, 685-690.	0.5	55
164	Contemporary Evaluation of the Dâ€™Amico Risk Classification of Prostate Cancer. Urology, 2007, 70, 931-935.	0.5	111
165	Low risk prostate cancer in men under age 65: The case for definitive treatment. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 510-514.	0.8	22
166	Prostate cancer risk among users of finasteride and alpha-blockers â€“ A population based caseâ€“control study. European Journal of Cancer, 2007, 43, 775-781.	1.3	11
168	Introduction and Conclusions. European Urology Supplements, 2007, 6, 695-700.	0.1	1
169	hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4â€“10 ng/ml. European Urology, 2007, 52, 1358-1364.	0.9	30
171	Under Diagnosis and Over Diagnosis of Prostate Cancer. Journal of Urology, 2007, 178, 88-92.	0.2	68
172	Under Diagnosis and Over Diagnosis of Prostate Cancer in a Screening Population With Serum PSA 2 to 10 ng/ml. Journal of Urology, 2007, 178, 93-97.	0.2	28
173	Expectant Management of Prostate Cancer With Curative Intent: An Update of The Johns Hopkins Experience. Journal of Urology, 2007, 178, 2359-2365.	0.2	308
174	â€œThe news is [not] all goodâ€“ misrepresentations and inaccuracies in Australian news media reports on prostate cancer screening. Medical Journal of Australia, 2007, 187, 507-510.	0.8	44
175	Nomogram use for the prediction of indolent prostate cancer. Cancer, 2007, 110, 2218-2221.	2.0	65
176	The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate, 2007, 67, 439-446.	1.2	27
177	Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. British Journal of Cancer, 2007, 96, 56-60.	2.9	19

#	ARTICLE	IF	CITATIONS
178	The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. <i>BJU International</i> , 2007, 99, 786-793.	1.3	161
179	Is the era of prostate-specific antigen over?. <i>BJU International</i> , 2007, 100, 8-10.	1.3	4
180	Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. <i>BJU International</i> , 2007, 100, 544-551.	1.3	107
181	PROSTATE-SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER: A DECISION-ANALYTICAL PERSPECTIVE. <i>BJU International</i> , 2007, 100, 486-488.	1.3	2
182	Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. <i>BJU International</i> , 2007, 101, 070915222359001-???.	1.3	141
183	Should We Replace the Gleason Score with the Amount of High-Grade Prostate Cancer?. <i>European Urology</i> , 2007, 51, 931-939.	0.9	46
184	Overall and Disease-Specific Survival of Patients with Screen-Detected Prostate Cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam. <i>European Urology</i> , 2007, 51, 366-374.	0.9	27
185	Active Surveillance for Prostate Cancers Detected in Three Subsequent Rounds of a Screening Trial: Characteristics, PSA Doubling Times, and Outcome. <i>European Urology</i> , 2007, 51, 1244-1251.	0.9	142
186	Cancer Detection and Cancer Characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) â€“ Section Rotterdam. <i>European Urology</i> , 2007, 52, 89-97.	0.9	98
188	The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic Value of Tumour Ploidy and Comorbidity. <i>European Urology</i> , 2007, 52, 1028-1035.	0.9	21
190	Advances in the Treatment of Prostate Cancer. <i>Annual Review of Medicine</i> , 2007, 58, 205-220.	5.0	30
191	Overdiagnosis and overtreatment of early detected prostate cancer. <i>World Journal of Urology</i> , 2007, 25, 3-9.	1.2	139
193	Active surveillance for favorable-risk prostate cancer: What are the results and how safe is it?. <i>Current Urology Reports</i> , 2007, 8, 341-344.	1.0	4
194	Prostate Cancer Testing following a Negative Prostate Biopsy: Over Testing the Elderly. <i>Journal of General Internal Medicine</i> , 2007, 22, 1139-1143.	1.3	7
195	What is low-risk prostate cancer and what is its natural history?. <i>World Journal of Urology</i> , 2008, 26, 415-422.	1.2	27
196	Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?. <i>World Journal of Urology</i> , 2008, 26, 457-467.	1.2	39
197	Active surveillance for prostate cancer: trials and tribulations. <i>World Journal of Urology</i> , 2008, 26, 437-442.	1.2	61
198	Watchful waiting versus active surveillance: Appropriate patient selection. <i>Current Urology Reports</i> , 2008, 9, 211-216.	1.0	10

#	ARTICLE	IF	CITATIONS
202	Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. <i>Prostate</i> , 2008, 68, 1179-1186.	1.2	23
203	Predicting survival for men with clinically localized prostate cancer. <i>Cancer</i> , 2008, 112, 1-3.	2.0	15
204	Negative influence of changing biopsy practice patterns on the predictive value of prostate-specific antigen for cancer detection on prostate biopsy. <i>Cancer</i> , 2008, 112, 1718-1725.	2.0	7
205	Active surveillance for early-stage prostate cancer. <i>Cancer</i> , 2008, 112, 1650-1659.	2.0	252
206	Should patients consider active surveillance?. <i>Cancer</i> , 2008, 112, 2631-2634.	2.0	3
207	Prostate-specific antigen screening among young men in the United States. <i>Cancer</i> , 2008, 113, 1315-1323.	2.0	28
208	Perceived family history risk and symptomatic diagnosis of prostate cancer. <i>Cancer</i> , 2008, 113, 2180-2187.	2.0	21
209	Assessment of causes of death in a prostate cancer screening trial. <i>International Journal of Cancer</i> , 2008, 122, 413-417.	2.3	47
210	Lower urinary tract symptoms and risk of prostate cancer: The HUNT 2 Cohort, Norway. <i>International Journal of Cancer</i> , 2008, 123, 1924-1928.	2.3	44
211	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. <i>Clinical Chemistry</i> , 2008, 54, e11-e79.	1.5	539
212	Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends. <i>Biometrics</i> , 2008, 64, 10-19.	0.8	101
213	Survival from prostate cancer in England and Wales up to 2001. <i>British Journal of Cancer</i> , 2008, 99, S78-S79.	2.9	3
214	Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. <i>Nature Genetics</i> , 2008, 40, 1032-1034.	9.4	83
215	Prostate specific antigen (PSA)-based screening. <i>International Journal of Urology</i> , 2008, 15, 757-762.	0.5	4
216	Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. <i>BJU International</i> , 2008, 101, 547-555.	1.3	53
217	Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL. <i>BJU International</i> , 2008, 101, 1223-1226.	1.3	7
218	The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis. <i>BJU International</i> , 2008, 101, 1507-1512.	1.3	9
219	Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. <i>BJU International</i> , 2008, 101, 809-816.	1.3	120

#	ARTICLE	IF	CITATIONS
220	Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?. BJU International, 2008, 102, 24-27.	1.3	11
221	Watchful waiting and active surveillance: the current position. BJU International, 2008, 102, 10-14.	1.3	98
222	Overall Survival in the Intervention Arm of a Randomized Controlled Screening Trial for Prostate Cancer Compared with a Clinically Diagnosed Cohort. European Urology, 2008, 53, 91-98.	0.9	13
223	Screening for Prostate Cancer: An Update. European Urology, 2008, 53, 37-44.	0.9	43
224	Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men with Clinically High-Risk Prostate Cancer Treated with Radical Prostatectomy. European Urology, 2008, 53, 950-959.	0.9	174
225	Early Detection of Prostate Cancer in 2007. European Urology, 2008, 53, 468-477.	0.9	140
226	Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels <math>\leq 3.0\text{ng/ml}</math>? A Comparison of Biopsy Results of PCPT and Outcome-Related Information from ERSPC. European Urology, 2008, 53, 901-908.	0.9	31
227	The Role of the Digital Rectal Examination in Subsequent Screening Visits in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. European Urology, 2008, 54, 581-588.	0.9	100
228	PSA-based Screening for Prostate Cancer: How Does It Compare with Other Cancer Screening Tests?. European Urology, 2008, 54, 262-273.	0.9	46
229	Active Surveillance for Favorable Risk Prostate Cancer: What Are the Results, and How Safe Is It?. Seminars in Radiation Oncology, 2008, 18, 2-6.	1.0	25
230	Advances in MR Spectroscopy of the Prostate. Magnetic Resonance Imaging Clinics of North America, 2008, 16, 697-710.	0.6	94
231	D'Épistage du cancer de la prostate: les arguments "contre". Medecine Nucleaire, 2008, 32, 41-45.	0.2	1
232	CpG Island Hypermethylation at Multiple Gene Sites in Diagnosis and Prognosis of Prostate Cancer. Urology, 2008, 71, 161-167.	0.5	120
233	Natural History of Pathologically Organ-Confined (pT2), Gleason Score 6 or Less, Prostate Cancer After Radical Prostatectomy. Urology, 2008, 72, 172-176.	0.5	73
234	Prostate Mechanical Imaging: A New Method for Prostate Assessment. Urology, 2008, 71, 425-429.	0.5	32
235	Statistical issues in the evaluation of screening and early detection modalities. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 308-315.	0.8	8
236	What is the best approach for screen-detected low volume cancers?"The case for observation. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 495-499.	0.8	11
237	Screening for prostate cancer (PC)"an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urologic Oncology: Seminars and Original Investigations, 2008, 26, 533-541.	0.8	38

#	ARTICLE	IF	CITATIONS
238	Recent trends in cancer survival across Europe between 2000 and 2004: A model-based period analysis from 12 cancer registries. <i>European Journal of Cancer</i> , 2008, 44, 1463-1475.	1.3	101
239	Qualitative research to improve RCT recruitment: Issues arising in establishing research collaborations. <i>Contemporary Clinical Trials</i> , 2008, 29, 663-670.	0.8	48
240	Quantifying the role of PSA screening in the US prostate cancer mortality decline. <i>Cancer Causes and Control</i> , 2008, 19, 175-181.	0.8	345
241	Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. <i>Lancet Oncology</i> , The, 2008, 9, 445-452.	5.1	231
243	Evaluation of Serum and Urinary Myeloid Related Protein-14 as a Marker for Early Detection of Prostate Cancer. <i>Journal of Urology</i> , 2008, 180, 1309-1313.	0.2	24
247	Comparison of Prostate Specific Antigen Velocity in Screened Versus Referred Patients With Prostate Cancer. <i>Journal of Urology</i> , 2008, 179, 1340-1343.	0.2	5
249	Meanings of prostate-specific antigen testing as narrated by men with localized prostate cancer after primary treatment. <i>Scandinavian Journal of Urology and Nephrology</i> , 2008, 42, 101-109.	1.4	4
250	Prostate specific antigen—brief update on its clinical use. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2008, 50, 19-24.	0.2	3
251	Outcomes Following Active Surveillance of Men With Localized Prostate Cancer Diagnosed in the Prostate Specific Antigen Era. <i>Journal of Urology</i> , 2008, 180, 1336-1341.	0.2	42
252	SPCG-4: A Needed START to PIVOTAL Data to Promote and Protect Evidence-Based Prostate Cancer Care. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1123-1125.	3.0	21
253	Screening for bladder cancer: Theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. <i>Scandinavian Journal of Urology and Nephrology</i> , 2008, 42, 191-212.	1.4	6
254	Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii45-ii46.	0.6	14
255	Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies. <i>Journal of the National Cancer Institute</i> , 2008, 100, 170-183.	3.0	708
256	What to Do with an Abnormal PSA Test. <i>Oncologist</i> , 2008, 13, 299-305.	1.9	48
257	Using qualitative research methods to improve recruitment to randomized controlled trials: The Quartet study. <i>Journal of Health Services Research and Policy</i> , 2008, 13, 92-96.	0.8	129
258	Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach. <i>Medical Decision Making</i> , 2008, 28, 323-331.	1.2	88
259	<i>Urological Oncology</i> , 2008, , .		3
260	Height and Prostate Cancer Risk: A Large Nested Case-Control Study (Protect) and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2325-2336.	1.1	83

#	ARTICLE	IF	CITATIONS
262	Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: The moderating role of age. <i>Psychology, Health and Medicine</i> , 2008, 13, 146-161.	1.3	23
263	Clinical Impact of New Prostate-Specific Antigen WHO Standardization on Biopsy Rates and Cancer Detection. <i>Clinical Chemistry</i> , 2008, 54, 1999-2006.	1.5	26
264	Baseline Prostate-Specific Antigen Level and Risk of Prostate Cancer and Prostate-Specific Mortality: Diagnosis Is Dependent on the Intensity of Investigation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 271-278.	1.1	28
265	Case 15-2008. <i>New England Journal of Medicine</i> , 2008, 358, 2161-2168.	13.9	8
266	Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. <i>Nature Reviews Urology</i> , 2008, 5, 277-283.	1.4	17
267	Should men over the age of 65 years receive PSA screening? Argument against. <i>Nature Reviews Urology</i> , 2008, 5, 232-233.	1.4	2
268	Recommending Mammography Screening beyond 80 Years of Age: A Time for Caution. <i>Women's Health</i> , 2008, 4, 333-335.	0.7	3
269	Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1144-1154.	3.0	552
270	Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer. <i>Annals of Internal Medicine</i> , 2008, 148, 435.	2.0	505
271	Current clinical issues in prostate cancer that can be addressed by imaging. , 0, , 29-42.		0
272	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. <i>Annals of Internal Medicine</i> , 2008, 149, 461.	2.0	263
273	Multiparametric magnetic resonance imaging in prostate cancer: present and future. <i>Current Opinion in Urology</i> , 2008, 18, 71-77.	0.9	198
274	Pesticides and prostate cancer: a review of epidemiologic studies with specific agricultural exposure information. <i>European Journal of Cancer Prevention</i> , 2008, 17, 97-110.	0.6	32
275	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in the Evaluation of the Prostate. <i>Topics in Magnetic Resonance Imaging</i> , 2008, 19, 273-284.	0.7	46
276	Imaging low-risk prostate cancer. <i>Current Opinion in Urology</i> , 2008, 18, 78-86.	0.9	11
277	PSA Doubling Time as a Predictor of the Outcome of Random Prostate Biopsies Prompted by Isolated PSA Elevation in Subjects Referred to an Outpatient Biopsy Facility in a Routine Clinical Scenario. <i>International Journal of Biological Markers</i> , 2008, 23, 187-191.	0.7	1
278	Prostate cancer and prostate-specific antigen testing in New South Wales. <i>Medical Journal of Australia</i> , 2008, 189, 315-318.	0.8	31
279	Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group. <i>Current Oncology</i> , 2008, 15, 179-184.	0.9	7

#	ARTICLE	IF	CITATIONS
280	The natural and treated history of prostate cancer. , 0, , 15-28.		2
281	Screening for prostate cancer: explaining new trial results and their implications to patients. Medical Journal of Australia, 2009, 191, 226-229.	0.8	12
282	Espectroscopia por ressonância magnética no diagnóstico do câncer de próstata: experiência inicial. Radiologia Brasileira, 2009, 42, 1-6.	0.3	9
283	The Japanese Guideline for Prostate Cancer Screening. Japanese Journal of Clinical Oncology, 2009, 39, 339-351.	0.6	32
284	Patients' Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status. Journal of the American Board of Family Medicine, 2009, 22, 247-256.	0.8	28
285	Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era. Journal of Clinical Oncology, 2009, 27, 4300-4305.	0.8	417
286	Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. British Journal of Cancer, 2009, 100, 1198-1204.	2.9	58
287	Promoter Methylation in <i>APC</i> , <i>RUNX3</i> , and <i>GSTP1</i> and Mortality in Prostate Cancer Patients. Journal of Clinical Oncology, 2009, 27, 3161-3168.	0.8	137
288	Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Annals of Oncology, 2009, 20, 564-573.	0.6	97
289	Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. Journal of Health Services Research and Policy, 2009, 14, 77-81.	0.8	16
290	A challenge to contemporary management of prostate cancer. Nature Reviews Urology, 2009, 6, 12-13.	1.4	16
291	Outcomes of Localized Prostate Cancer Following Conservative Management. JAMA - Journal of the American Medical Association, 2009, 302, 1202.	3.8	366
292	The other side of technology: risk of overdiagnosis of breast cancer with mammography screening. Future Oncology, 2009, 5, 481-491.	1.1	10
293	Prostate-Cancer Screening. New England Journal of Medicine, 2009, 361, 202-206.	13.9	15
294	To screen or not to screen?. Nature Reviews Urology, 2009, 6, 299-301.	1.9	4
295	A Model of Prostate-Specific Antigen Screening Outcomes for Low- to High-Risk Men. Archives of Internal Medicine, 2009, 169, 1603-10.	4.3	37
297	Prostate-Specific Antigen Testing among the Elderly in Community-Based Family Medicine Practices. Journal of the American Board of Family Medicine, 2009, 22, 257-265.	0.8	14
298	Association of Diabetes and Body Mass Index with Levels of Prostate-Specific Antigen: Implications for Correction of Prostate-Specific Antigen Cutoff Values?. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1350-1356.	1.1	55

#	ARTICLE	IF	CITATIONS
299	Prostate cancer treatment in Europe at the end of 1990s. <i>Acta Oncologica</i> , 2009, 48, 867-873.	0.8	11
300	Annual screening for prostate cancer did not reduce mortality from prostate cancer. <i>Evidence-Based Medicine</i> , 2009, 14, 104-105.	0.6	6
301	Prostatakarzinom. , 2009, , 485-635.		0
302	Test Sensitivity in the European Prostate Cancer Screening Trial: Results from Finland, Sweden, and the Netherlands. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2000-2005.	1.1	10
303	Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1325-1329.	3.0	508
304	Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7316-7321.	3.2	57
305	An Iatrogenic Confounding Variable. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1368-1369.	3.0	2
306	Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context. <i>Journal of the National Cancer Institute</i> , 2009, 101, 374-383.	3.0	668
307	Screening for Prostate Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2009, 59, 264-273.	157.7	90
308	Analysis of T1c Prostate Cancers Treated at Very Low Prostate-Specific Antigen Levels. <i>European Urology</i> , 2009, 55, 610-616.	0.9	8
309	Editorial Comment on: Analysis of T1c Prostate Cancers Treated at Very Low Prostate-Specific Antigen Levels. <i>European Urology</i> , 2009, 55, 616.	0.9	0
310	Time, Symptom Burden, Androgen Deprivation, and Self-Assessed Quality of Life after Radical Prostatectomy or Watchful Waiting: The Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) Clinical Trial. <i>European Urology</i> , 2009, 55, 422-432.	0.9	93
311	Editorial Comment on: Time, Symptom Burden, Androgen Deprivation, and Self-Assessed Quality of Life after Radical Prostatectomy or Watchful Waiting: The Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) Clinical Trial. <i>European Urology</i> , 2009, 55, 432.	0.9	1
312	Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly. <i>European Urology</i> , 2009, 55, 1-8.	0.9	242
313	The Treatment Paradigm Shifts Again on Prostate Cancer. <i>European Urology</i> , 2009, 55, 9-11.	0.9	4
315	Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based Screening for Prostate Cancer: How Does It Compare with Other Cancer Screening Tests? <i>Eur Urol</i> 2008;54:262-73. <i>European Urology</i> , 2009, 55, e88-e89.	0.9	1
316	Re: Radical Prostatectomy versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. <i>European Urology</i> , 2009, 55, 989-990.	0.9	3
317	Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications. <i>European Urology</i> , 2009, 55, 1321-1332.	0.9	155

#	ARTICLE	IF	CITATIONS
318	Editorial Comment on: Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications. <i>European Urology</i> , 2009, 55, 1331.	0.9	2
319	Editorial Comment on: Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications. <i>European Urology</i> , 2009, 55, 1331-1332.	0.9	2
320	Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). <i>European Urology</i> , 2009, 56, 584-591.	0.9	180
321	Lies, Damn Lies, and Cancer Statistics. <i>European Urology</i> , 2009, 56, 592-593.	0.9	1
322	Conundrums in screening for cancer. <i>International Journal of Cancer</i> , 2010, 126, 1039-1046.	2.3	25
323	Prostate cancer regulatory networks. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 845-852.	1.2	32
324	International epidemiology of prostate cancer: Geographical distribution and secular trends. <i>Molecular Nutrition and Food Research</i> , 2009, 53, 171-184.	1.5	350
325	Classification of prostatic diseases by means of multivariate analysis on <i>in vivo</i> proton MRSI and DCE-MRI data. <i>NMR in Biomedicine</i> , 2009, 22, 1036-1046.	1.6	8
327	Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience. <i>Clinical and Translational Oncology</i> , 2009, 11, 470-478.	1.2	20
328	Watchful waiting versus active surveillance: Appropriate patient selection. <i>Current Prostate Reports</i> , 2009, 7, 5-10.	0.1	0
329	Stage-specific cancer incidence: An artificially mixed multinomial logit model. <i>Statistics in Medicine</i> , 2009, 28, 2054-2076.	0.8	6
330	The overdiagnosis nightmare: a time for caution. <i>BMC Women's Health</i> , 2009, 9, 34.	0.8	7
331	Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. <i>British Journal of Cancer</i> , 2009, 101, 1833-1838.	2.9	134
332	Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens. <i>BJU International</i> , 2009, 103, 1190-1194.	1.3	67
333	Prostate cancer: a serious disease suitable for prevention. <i>BJU International</i> , 2009, 103, 864-870.	1.3	38
334	Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. <i>BJU International</i> , 2009, 103, 1472-1477.	1.3	42
335	Screening: should more biopsies be taken in larger prostates?. <i>BJU International</i> , 2009, 104, 919-924.	1.3	6
336	Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. <i>BJU International</i> , 2009, 104, 1592-1598.	1.3	69

#	ARTICLE	IF	CITATIONS
337	Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. <i>Journal of Proteomics</i> , 2009, 72, 907-917.	1.2	76
339	Treatment of early prostate cancer: active surveillance. <i>Trends in Urology Gynaecology &amp; Sexual Health</i> , 2009, 14, 15-19.	0.1	2
340	Does Race Affect Postoperative Outcomes in Patients With Low-Risk Prostate Cancer Who Undergo Radical Prostatectomy?. <i>Urology</i> , 2009, 73, 620-623.	0.5	40
341	A Multi-Institutional Evaluation of Active Surveillance for Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2009, 181, 1635-1641.	0.2	121
342	Review of Diagnostic Markers for Prostate Cancer 16. <i>Recent Results in Cancer Research</i> , 2009, 181, 173-182.	1.8	23
345	Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines. <i>Pharmacoeconomics</i> , 2009, 27, 533-545.	1.7	99
346	Prostate Cancer: New Insights into Minimal and Localised Disease: Active Surveillance. <i>European Urology Supplements</i> , 2009, 8, 718-720.	0.1	1
347	Trials of prostate-cancer screening are not worthwhile. <i>Lancet Oncology</i> , The, 2009, 10, 294-298.	5.1	53
348	Mortality Results from a Randomized Prostate-Cancer Screening Trial. <i>New England Journal of Medicine</i> , 2009, 360, 1310-1319.	13.9	2,592
349	Screening and Prostate-Cancer Mortality in a Randomized European Study. <i>New England Journal of Medicine</i> , 2009, 360, 1320-1328.	13.9	3,540
350	Pathological Outcomes of Candidates for Active Surveillance of Prostate Cancer. <i>Journal of Urology</i> , 2009, 181, 1628-1634.	0.2	162
351	Radical Prostatectomy Findings in Patients in Whom Active Surveillance of Prostate Cancer Fails. <i>Journal of Urology</i> , 2009, 182, 2274-2279.	0.2	131
352	Patient selection for focal therapy of localized prostate cancer. <i>Current Opinion in Urology</i> , 2009, 19, 268-273.	0.9	28
353	Prostate-specific antigen screening and prostate cancer mortality: implications of a randomized European study. <i>Aging Health</i> , 2009, 5, 281-286.	0.3	1
354	Annual screening for prostate cancer did not reduce mortality from prostate cancer. <i>Annals of Internal Medicine</i> , 2009, 150, JC6.	2.0	1
355	False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up. <i>American Journal of Surgical Pathology</i> , 2010, 34, 35-43.	2.1	120
356	Randomized trial results did not resolve controversies surrounding prostate cancer screening. <i>Current Opinion in Urology</i> , 2010, 20, 189-193.	0.9	11
357	Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 162-200.	2.3	671

#	ARTICLE	IF	CITATIONS
358	A Method for Using Life Tables to Estimate Lifetime Risk for Prostate Cancer Death. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 148-154.	2.3	12
360	Genitourinary Functioning and Depressive Symptoms Over Time In Younger Versus Older Men Treated for Prostate Cancer. Annals of Behavioral Medicine, 2010, 40, 275-283.	1.7	19
361	Active Surveillance for Prostate Cancer: A Review. Current Urology Reports, 2010, 11, 165-171.	1.0	77
362	Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland. Cancer Causes and Control, 2010, 21, 1523-1531.	0.8	20
363	Managing benign prostatic hyperplasia and prostate cancer – the challenges today. Journal of Men's Health, 2010, 7, 113-124.	0.1	2
364	Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering?. BMC Cancer, 2010, 10, 251.	1.1	5
365	Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts. European Urology, 2010, 57, 446-452.	0.9	12
366	Editorial Comment on: Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts. European Urology, 2010, 57, 452.	0.9	1
367	A Risk-Based Strategy Improves Prostate-Specific Antigen-Driven Detection of Prostate Cancer. European Urology, 2010, 57, 79-85.	0.9	245
368	Focal Therapy for Prostate Cancer: Possibilities and Limitations. European Urology, 2010, 58, 57-64.	0.9	95
369	Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?. Cancer, 2010, 116, 1281-1290.	2.0	97
370	Balancing the harms and benefits of early detection of prostate cancer. Cancer, 2010, 116, 4857-4865.	2.0	37
371	The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. International Journal of Cancer, 2010, 126, 2387-2393.	2.3	68
372	Innovative biomarkers for prostate cancer early diagnosis and progression. Critical Reviews in Oncology/Hematology, 2010, 73, 10-22.	2.0	44
373	Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians. International Journal of Clinical Practice, 2010, 64, 1740-1745.	0.8	35
374	DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme. BJU International, 2010, 105, 329-333.	1.3	14
375	SERUM TESTOSTERONE IS ASSOCIATED WITH AGGRESSIVE PROSTATE CANCER IN OLDER MEN: RESULTS FROM THE BALTIMORE LONGITUDINAL STUDY OF AGING. BJU International, 2010, 105, 884-885.	1.3	4
377	PREOPERATIVE ASSESSMENT FOR MAJOR UROLOGICAL SURGERY: WHERE ARE WE NOW?. BJU International, 2010, 105, 886-886.	1.3	0

#	ARTICLE	IF	CITATIONS
378	ROBOT-ASSISTED RADICAL PROSTATECTOMY IN MEN AGED ≥70 YEARS. <i>BJU International</i> , 2010, 105, 886-887.		4
379	The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number. <i>BJU International</i> , 2010, 106, 1293-1297.	1.3	10
380	Prostate cancer: risk factors, diagnosis and management. <i>Cancer Nursing Practice</i> , 2010, 9, 29-36.	0.2	6
381	PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer. <i>Scientific World Journal</i> , The, 2010, 10, 1919-1931.	0.8	66
382	A descriptive study of prostate cancer mortality in the state of São Paulo, from 1980 to 2007. <i>Einstein (Sao Paulo, Brazil)</i> , 2010, 8, 433-436.	0.3	2
383	The future burden of cancer in London compared with England. <i>Journal of Public Health</i> , 2010, 32, 83-89.	1.0	6
384	Overdiagnosis in Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 605-613.	3.0	1,392
385	Screening for Breast and Prostate Cancers: Moving Toward Transparency. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1008-1011.	3.0	20
386	Screening for prostate cancer: have we resolved the controversy?. <i>Current Opinion in Supportive and Palliative Care</i> , 2010, 4, 121-126.	0.5	3
387	Lowering the PSA Threshold for Prostate Biopsy from 4 to 2.5 ng/ml: Influence on Cancer Characteristics and Number of Men Needed to Biopt. <i>Urologia Internationalis</i> , 2010, 84, 141-146.	0.6	4
388	Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. <i>Biostatistics</i> , 2010, 11, 707-719.	0.9	45
389	Prostate cancer screening: current status and future perspectives. <i>Nature Reviews Urology</i> , 2010, 7, 487-493.	1.9	64
390	Proteomics in prostate cancer biomarker discovery. <i>Expert Review of Proteomics</i> , 2010, 7, 93-102.	1.3	16
391	Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1201-1207.	1.1	30
392	Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program. <i>Journal of Clinical Oncology</i> , 2010, 28, 2810-2816.	0.8	237
393	Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer—Rotterdam. <i>Journal of the National Cancer Institute</i> , 2010, 102, 352-355.	3.0	51
394	The prostate cancer pseudo-epidemic. <i>Acta Oncológica</i> , 2010, 49, 298-304.	0.8	21
395	The implementation of screening for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 218-227.	2.0	13

#	ARTICLE	IF	CITATIONS
396	Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study. <i>Journal of the National Cancer Institute</i> , 2010, 102, 950-958.	3.0	211
397	Should prostate-specific antigen screening be offered to asymptomatic men?. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1043-1053.	1.1	4
398	Focal Laser Ablation for Localized Prostate Cancer. <i>Journal of Endourology</i> , 2010, 24, 791-797.	1.1	49
399	Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. <i>Journal of Urology</i> , 2010, 183, 534-538.	0.2	119
401	Prostate-specific Antigen Testing and Prostate Cancer Screening. <i>Primary Care - Clinics in Office Practice</i> , 2010, 37, 441-459.	0.7	11
402	Eligibility for Active Surveillance and Pathological Outcomes for Men Undergoing Radical Prostatectomy in a Large, Community Based Cohort. <i>Journal of Urology</i> , 2010, 183, 138-144.	0.2	35
403	Chemoprevention of Prostate Cancer. <i>Urologic Clinics of North America</i> , 2010, 37, 11-21.	0.8	16
404	Treatment of localized prostate cancer: when is active surveillance appropriate?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 394-400.	12.5	35
405	Risk Stratification of Men Choosing Surveillance for Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2010, 183, 1779-1785.	0.2	88
407	In-Depth Proteomic Analyses of Direct Expressed Prostatic Secretions. <i>Journal of Proteome Research</i> , 2010, 9, 2109-2116.	1.8	57
408	Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 341, c4543-c4543.	2.4	257
409	Informed decision making on PSA testing for the detection of prostate cancer: An evaluation of a leaflet with risk indicator. <i>European Journal of Cancer</i> , 2010, 46, 669-677.	1.3	20
410	PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. <i>European Journal of Cancer</i> , 2010, 46, 3053-3060.	1.3	18
411	On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. <i>European Journal of Cancer</i> , 2010, 46, 3109-3119.	1.3	20
412	Lead-time in the European Randomised Study of Screening for Prostate Cancer. <i>European Journal of Cancer</i> , 2010, 46, 3102-3108.	1.3	53
413	Prediction of Mortality After Radical Prostatectomy by Charlson Comorbidity Index. <i>Urology</i> , 2010, 76, 553-557.	0.5	77
414	What can be concluded from the ERSPC and PLCO trial data?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 668-669.	0.8	16
415	Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964-2003 followed up until the end of 2006. <i>Acta Oncologica</i> , 2010, 49, 644-654.	0.8	47

#	ARTICLE	IF	CITATIONS
416	Integrating Evidence and Individual Preferences Using a Web-Based Multi-Criteria Decision Analytic Tool. <i>Patient</i> , 2011, 4, 153-162.	1.1	20
417	Co-registration Framework for Histology-registration-based Validation of Fused Multimodality Prostate Cancer Imaging. , 2011, , .		0
418	Major Urologic Problems in Geriatrics: Assessment and Management. <i>Medical Clinics of North America</i> , 2011, 95, 253-264.	1.1	13
419	A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial. <i>Journal of Urology</i> , 2011, 185, 121-125.	0.2	248
420	Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2011, 35, 589-596.	0.2	17
421	Valor de referencia del cambio del PSA en la evaluación del riesgo de cáncer de próstata. <i>Revista Del Laboratorio Clínico</i> , 2011, 4, 115-120.	0.1	0
422	Dynamic Microsimulation Models for Health Outcomes. <i>Medical Decision Making</i> , 2011, 31, 10-18.	1.2	144
423	Cancer in Long-Term Care. <i>Clinics in Geriatric Medicine</i> , 2011, 27, 301-327.	1.0	2
424	Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A single-institution experience of 356 patients. <i>European Journal of Radiology</i> , 2011, 77, 340-345.	1.2	106
425	Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1412-1417.	2.4	43
426	Cancer screening in older adults: What to do when we don't know. <i>Journal of Geriatric Oncology</i> , 2011, 2, 149-160.	0.5	7
427	The Prostate-Specific Antigen Screening Conundrum: Examining the Evidence. <i>Seminars in Oncology Nursing</i> , 2011, 27, 251-259.	0.7	6
428	ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program. <i>Urology</i> , 2011, 77, 763.e1-763.e6.	0.5	47
429	Acceptance and Durability of Surveillance as a Management Choice in Men with Screen-detected, Low-risk Prostate Cancer: Improved Outcomes with Stringent Enrollment Criteria. <i>Urology</i> , 2011, 77, 980-984.	0.5	28
430	Screening for prostate cancer. <i>European Journal of Cancer</i> , 2011, 47, S164-S170.	1.3	25
431	Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. <i>Lancet Oncology</i> , The, 2011, 12, 891-899.	5.1	311
432	The Relationship Between Prostate Specific Antigen Change and Biopsy Progression in Patients on Active Surveillance for Prostate Cancer. <i>Journal of Urology</i> , 2011, 185, 1656-1660.	0.2	103
433	Significance of Prostate Adenocarcinoma Perineural Invasion on Biopsy in Patients Who are Otherwise Candidates for Active Surveillance. <i>Journal of Urology</i> , 2011, 186, 470-473.	0.2	29

#	ARTICLE	IF	CITATIONS
434	PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making. <i>Asian Journal of Andrology</i> , 2011, 13, 219-224.	0.8	21
435	Nomogram to Predict Insignificant Prostate Cancer at Radical Prostatectomy in Korean Men: A Multi-Center Study. <i>Yonsei Medical Journal</i> , 2011, 52, 74.	0.9	8
436	Niveles s�ricos del ant�geno prost�tico espec�fico en varones expuestos y no expuestos al ars�nico en el agua de bebida en Tucum�n, Argentina. <i>Revista Medica De Chile</i> , 2011, 139, 1581-1587.	0.1	1
437	Contemporary role of prostate cancer gene 3 in the management of prostate cancer. <i>Current Opinion in Urology</i> , 2011, 21, 225-229.	0.9	21
438	Update on Screening in Prostate Cancer Based on Recent Clinical Trials. <i>Reviews on Recent Clinical Trials</i> , 2011, 6, 7-15.	0.4	6
439	Prostate-specific antigen screening in elderly men. <i>Aging Health</i> , 2011, 7, 219-229.	0.3	0
440	Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2011, 155, 762.	2.0	485
441	Radical prostatectomy reduced mortality and disease progression over the long term more than watchful waiting in early prostate cancer. <i>Annals of Internal Medicine</i> , 2011, 155, JC1-2.	2.0	1
442	A prospective, randomized trial comparing the Vienna nomogram to an eight-core prostate biopsy protocol. <i>BJU International</i> , 2011, 108, 204-208.	1.3	14
443	Screening for prostate cancer: an updated Cochrane systematic review. <i>BJU International</i> , 2011, 107, 882-891.	1.3	147
444	Maximizing outcomes in genitourinary cancers across the treatment continuum. <i>BJU International</i> , 2011, 107, 1-12.	1.3	1
445	Cysteine-rich secretory protein 3 and �microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome. <i>BJU International</i> , 2011, 108, 1356-1362.	1.3	8
446	Management of low (favourable)-risk prostate cancer. <i>BJU International</i> , 2011, 108, 1684-1695.	1.3	27
447	Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. <i>BJU International</i> , 2011, 108, 1402-1408.	1.3	63
448	Dramatic increase in prostate cancer cases by 2021. <i>BJU International</i> , 2011, 108, 1734-1738.	1.3	35
449	Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. <i>BJU International</i> , 2011, 108, 1787-1793.	1.3	50
450	Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants. <i>BJU International</i> , 2011, 108, 1739-1742.	1.3	16
451	Perspective on prostate cancer screening. <i>International Journal of Clinical Practice</i> , 2011, 65, 31-34.	0.8	3

#	ARTICLE	IF	CITATIONS
452	Use of electronic medical records to identify patients at risk for prostate cancer in an academic institution. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 85-89.	2.0	3
453	Population-based screening for prostate cancer: the clinical conundrum. <i>Journal of Men's Health</i> , 2011, 8, 170-174.	0.1	0
454	Is Prostate Cancer Screening Bad or Good? Summary of a Debate at the Innovation in Urology Meeting, September 17-19, 2010, Milan, Italy. <i>European Urology</i> , 2011, 59, 359-362.	0.9	6
455	Re: Delay of Surgery in Men with Low-Risk Prostate Cancer. <i>European Urology</i> , 2011, 60, 597-598.	0.9	1
456	Re: Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study. <i>European Urology</i> , 2011, 60, 598-599.	0.9	0
457	Propensity Score Matching, Competing Risk Analysis, and a Competing Risk Nomogram: Some Guidance for Urologists May Be in Place. <i>European Urology</i> , 2011, 60, 931-933.	0.9	7
459	Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 310-316.	0.8	17
462	Assessing critical illness trends: the facts behind the stats. <i>European Actuarial Journal</i> , 2011, 1, 61-84.	0.5	1
463	Watchful Waiting and Active Surveillance Approach in Patients with Low Risk Localized Prostatic Cancer: An Experience of Out-Patients Clinic with 12-Year Follow-Up. <i>Pathology and Oncology Research</i> , 2011, 17, 893-897.	0.9	2
464	Aberrant glycosylation associated with enzymes as cancer biomarkers. <i>Clinical Proteomics</i> , 2011, 8, 7.	1.1	200
465	MRI of the prostate: Clinical relevance and emerging applications. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 33, 258-274.	1.9	43
466	Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. <i>Cancer</i> , 2011, 117, 1210-1219.	2.0	121
467	Speaker abstracts. <i>International Journal of Cancer</i> , 2011, 128, 1-28.	2.3	0
469	Development and pilot testing of an online screening decision aid for men with a family history of prostate cancer. <i>Patient Education and Counseling</i> , 2011, 83, 64-72.	1.0	25
470	Randomised prostate cancer screening trial: 20 year follow-up. <i>BMJ: British Medical Journal</i> , 2011, 342, d1539-d1539.	2.4	134
471	Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer. <i>Journal of Oncology Practice</i> , 2011, 7, e1-e5.	2.5	27
472	Screening for prostate cancer – The controversy continues, but can it be resolved?. <i>Acta Oncologica</i> , 2011, 50, 4-11.	0.8	16
473	When is active surveillance the appropriate treatment for prostate cancer?. <i>Acta Oncologica</i> , 2011, 50, 120-126.	0.8	15

#	ARTICLE	IF	CITATIONS
474	How Does Early Detection by Screening Affect Disease Progression?. <i>Medical Decision Making</i> , 2011, 31, 550-558.	1.2	35
475	Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1335-1341.	0.8	266
476	Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. <i>Journal of Clinical Oncology</i> , 2011, 29, 2185-2190.	0.8	545
477	What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 740-750.	1.1	43
478	The Science and Art of Prostate Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2011, 103, 450-451.	3.0	7
479	Active Surveillance for Prostate Cancer: An Underutilized Opportunity for Reducing Harm. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 175-183.	0.9	19
480	Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy. <i>Advances in Urology</i> , 2012, 2012, 1-7.	0.6	21
481	Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: A study from the National Prostate Cancer Register (NPCR) of Sweden. <i>Scandinavian Journal of Urology and Nephrology</i> , 2012, 46, 326-331.	1.4	10
482	Overdiagnosis of Prostate Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 146-151.	0.9	88
483	Prostate Cancer Aggressiveness: In Vivo Assessment of MR Spectroscopy and Diffusion-weighted Imaging at 3 T. <i>Radiology</i> , 2012, 265, 457-467.	3.6	127
484	To be screened or not to be screened? Modeling the consequences of PSA screening for the individual. <i>British Journal of Cancer</i> , 2012, 107, 778-784.	2.9	26
485	What Is the Risk Posed by Prostate Cancer?. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 169-174.	0.9	7
486	Patient Perspective on Watchful Waiting/Active Surveillance for Localized Prostate Cancer. <i>Journal of the American Board of Family Medicine</i> , 2012, 25, 763-770.	0.8	66
487	Trends in Prostate Cancer in the United States. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 152-156.	0.9	173
488	Cancer overdiagnosis and overtreatment. <i>Current Opinion in Urology</i> , 2012, 22, 203-209.	0.9	61
489	Risicofstratificatie en vroege opsporing van prostaatkanker. <i>Tijdschrift Voor Urologie</i> , 2012, 2, 184-189.	0.1	0
490	Prostate cancer screening. <i>Pathology</i> , 2012, 44, 99-109.	0.3	8
491	Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. <i>Annals of Internal Medicine</i> , 2012, 157, 120.	2.0	1,872

#	ARTICLE	IF	CITATIONS
492	Quality-of-Life Effects of Prostate-Specific Antigen Screening. <i>New England Journal of Medicine</i> , 2012, 367, 595-605.	13.9	364
493	Chapter 7: Description of MISCAN-Lung, the Erasmus MC Lung Cancer Microsimulation Model for Evaluating Cancer Control Interventions. <i>Risk Analysis</i> , 2012, 32, S85-98.	1.5	14
494	Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam. <i>BJU International</i> , 2012, 110, 1678-1683.	1.3	12
495	Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. <i>BJU International</i> , 2012, 110, 1672-1677.	1.3	125
496	Simulation optimization of PSA-threshold based prostate cancer screening policies. <i>Health Care Management Science</i> , 2012, 15, 293-309.	1.5	22
497	Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). <i>European Urology</i> , 2012, 62, 745-752.	0.9	216
498	Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 402-407.	0.8	7
499	Should warfarin or aspirin be stopped prior to prostate biopsy? An analysis of bleeding complications related to increasing sample number regimes. <i>Clinical Radiology</i> , 2012, 67, e64-e70.	0.5	42
501	Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 301-305.	0.8	33
502	A comparison of prostate cancer survival in England, Norway and Sweden: A population-based study. <i>Cancer Epidemiology</i> , 2012, 36, e7-e12.	0.8	13
503	Insensitivity to the growth inhibitory effects of activin A: An acquired capability in prostate cancer progression. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 119-125.	3.2	15
504	Landmarks in prostate cancer screening. <i>BJU International</i> , 2012, 110, 3-7.	1.3	30
505	Informed prostate cancer risk-adjusted testing: a new paradigm. <i>BJU International</i> , 2012, 110, 30-34.	1.3	6
506	Nuclear morphometry, nucleomics and prostate cancer progression. <i>Asian Journal of Andrology</i> , 2012, 14, 375-384.	0.8	25
507	Quality of Life and Guidelines for PSA Screening. <i>New England Journal of Medicine</i> , 2012, 367, 669-671.	13.9	39
508	Prostate-Cancer Mortality at 11 Years of Follow-up. <i>New England Journal of Medicine</i> , 2012, 366, 981-990.	13.9	1,105
509	Causes of Death After Radical Prostatectomy at a Large Tertiary Center. <i>Journal of Urology</i> , 2012, 188, 798-802.	0.2	23
510	Cancer as a disease of tissue pattern formation. <i>Progress in Histochemistry and Cytochemistry</i> , 2012, 47, 175-207.	5.1	12

#	ARTICLE	IF	CITATIONS
511	Treatment of Localized Prostate Cancer. , 2012, , 141-154.		0
512	The Epigenetic promise for prostate cancer diagnosis. Prostate, 2012, 72, 1248-1261.	1.2	126
513	The Dynamics of Death in Prostate Cancer. American Journal of Clinical Pathology, 2012, 137, 957-962.	0.4	10
514	Prostate cancer and androgenic alopecia. Expert Review of Endocrinology and Metabolism, 2012, 7, 169-173.	1.2	0
515	Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU International, 2012, 109, 1315-1322.	1.3	93
516	Number of screens for overdiagnosis as an indicator of absolute risk of overdiagnosis in prostate cancer screening. International Journal of Cancer, 2012, 131, 1367-1375.	2.3	17
517	Selective detection of aggressive prostate cancer. Cancer, 2012, 118, 2568-2570.	2.0	0
518	The prostate cancer conundrum revisited. Cancer, 2012, 118, 5955-5963.	2.0	125
519	The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes and Control, 2012, 23, 827-835.	0.8	61
520	Prostate cancer epidemiology in the United States. World Journal of Urology, 2012, 30, 195-200.	1.2	271
521	Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU International, 2012, 109, 1-7.	1.3	17
522	Predictors of Unfavourable Repeat Biopsy Results in Men Participating in a Prospective Active Surveillance Program. European Urology, 2012, 61, 370-377.	0.9	64
524	Risk-Based Prostate Cancer Screening. European Urology, 2012, 61, 652-661.	0.9	102
525	Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized Trial. European Urology, 2012, 61, 1110-1114.	0.9	269
526	The Impact of Interscreening Interval and Age on Prostate Cancer Screening With Prostate-Specific Antigen. European Urology, 2012, 61, 1011-1018.	0.9	17
527	Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer. European Urology, 2012, 61, 851-854.	0.9	11
528	Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort. BJU International, 2012, 110, 195-200.	1.3	19
529	Increased non-prostate cancer death risk in clinically diagnosed prostate cancer. BJU International, 2012, 110, 188-194.	1.3	2

#	ARTICLE	IF	CITATIONS
530	Effect of treatment with 5 $\alpha$ -reductase inhibitors on progression in monitored men with favourable risk prostate cancer. <i>BJU International</i> , 2012, 110, 651-657.	1.3	34
531	A stochastic model for survival of early prostate cancer with adjustments for leadtime, length bias, and overdiagnosis. <i>Biometrical Journal</i> , 2012, 54, 20-44.	0.6	14
532	From prostate-specific antigen (<scp>PSA</scp>) to precursor <scp>PSA</scp> (<scp>proPSA</scp>) isoforms: a review of the emerging role of <scp>proPSAs</scp> in the detection and management of early prostate cancer. <i>BJU International</i> , 2013, 112, 717-728.	1.3	58
534	Prostate Cancer Diagnosis. , 2013, , .		3
535	Screening for Prostate Cancer. , 2013, , 333-346.		2
536	Pathological Outcomes in Men with Low Risk and Very Low Risk Prostate Cancer: Implications on the Practice of Active Surveillance. <i>Journal of Urology</i> , 2013, 190, 1218-1223.	0.2	89
538	Role of Imaging as an Adjunct or Replacement for Biopsy: American Experience. , 2013, , 309-336.		1
539	Multiparametric Magnetic Resonance Imaging Approaches in Focal Prostate Cancer Therapy. , 2013, , 173-202.		1
540	Early Detection, PSA Screening, and Management of Overdiagnosis. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1091-1110.	0.9	9
541	Prostatic biopsies in selected men aged 75 years and older guide key clinical management decisions. <i>International Urology and Nephrology</i> , 2013, 45, 1539-1544.	0.6	1
542	The prostate-specific antigen test. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 423-426.	1.6	6
543	Overdiagnosis of breast cancer. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a.	2.3	5
544	The Study of Active Monitoring in Sweden (SAMS): A randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. <i>Scandinavian Journal of Urology</i> , 2013, 47, 347-355.	0.6	25
545	Outcome Following Active Surveillance of Men with Screen-detected Prostate Cancer. Results from the Göteborg Randomised Population-based Prostate Cancer Screening Trial. <i>European Urology</i> , 2013, 63, 101-107.	0.9	154
546	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162.	0.6	137
547	Value of transrectal power Doppler sonography in the detection of low-risk prostate cancers. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 60-67.	1.8	17
548	Reply from Authors re: Michael Baum. Screening for Prostate Cancer: Can We Learn from the Mistakes of the Breast Screening Experience? <i>Eur Urol</i> 2013;64:540-1. <i>European Urology</i> , 2013, 64, 541-543.	0.9	3
549	A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. <i>European Urology</i> , 2013, 63, 627-633.	0.9	34

#	ARTICLE	IF	CITATIONS
550	Differences in survival from prostate cancer in Denmark, Iceland and Sweden. <i>European Journal of Cancer</i> , 2013, 49, 1984-1992.	1.3	13
551	Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. <i>European Journal of Cancer</i> , 2013, 49, 3041-3048.	1.3	12
552	Life expectancy estimates as a key factor in over-treatment: The case of prostate cancer. <i>Cancer Epidemiology</i> , 2013, 37, 462-468.	0.8	19
553	Manipulating the epigenome for the treatment of urological malignancies. , 2013, 138, 185-196.		17
554	R�le de lâ€™�cho-Doppler puissance dans la d�tection des cancers � bas risque de la prostate. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 60-67.	0.0	0
555	Timing of Curative Treatment for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2013, 64, 204-215.	0.9	112
556	Active surveillance for low-risk prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 295-302.	2.0	46
557	Treatment of local�regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors. <i>British Journal of Cancer</i> , 2013, 108, 1971-1977.	2.9	13
558	Model-based patterns in prostate cancer mortality worldwide. <i>British Journal of Cancer</i> , 2013, 108, 2354-2366.	2.9	18
559	Screening for prostate cancer. <i>The Cochrane Library</i> , 2013, 2013, CD004720.	1.5	452
560	A Multi-Institutional Evaluation of Active Surveillance for Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2013, 189, S19-25; discussion S25.	0.2	59
561	Primer of Geriatric Urology. , 2013, , .		1
562	MR Imaging�guided Focal Laser Ablation for Prostate Cancer: Phase I Trial. <i>Radiology</i> , 2013, 267, 932-940.	3.6	178
563	Defining the threshold for significant versus insignificant prostate cancer. <i>Nature Reviews Urology</i> , 2013, 10, 473-482.	1.9	98
564	Optimal use of prostate specific antigen for prostate cancer screening. <i>Vojnosanitetski Pregled</i> , 2013, 70, 501-503.	0.1	1
565	Cancer Incidence in World Trade Center Rescue and Recovery Workers, 2001�2008. <i>Environmental Health Perspectives</i> , 2013, 121, 699-704.	2.8	99
566	Clonal Progression of Prostate Cancers from Gleason Grade 3 to Grade 4. <i>Cancer Research</i> , 2013, 73, 1050-1055.	0.4	85
567	False myths and legends in laboratory diagnostics. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2087-2097.	1.4	11

#	ARTICLE	IF	CITATIONS
568	Danish General Practitioners' Use of Prostate-Specific Antigen in Opportunistic Screening for Prostate Cancer: A Survey Comprising 174 GPs. <i>International Journal of Family Medicine</i> , 2013, 2013, 1-6.	1.2	12
569	Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. <i>British Journal of Cancer</i> , 2013, 109, 2014-2019.	2.9	83
570	Men's preferences for prostate cancer screening: a discrete choice experiment. <i>British Journal of Cancer</i> , 2013, 108, 533-541.	2.9	54
571	Second to fourth digit ratio and prostate cancer severity. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 107-110.	2.0	19
572	Interventions to encourage uptake of cancer screening for people with severe mental illness. , 2013, , CD009641.		4
573	Influence of Study Features and Methods on Overdiagnosis Estimates in Breast and Prostate Cancer Screening. <i>Annals of Internal Medicine</i> , 2013, 158, 831.	2.0	117
574	Comparative Effectiveness of Alternative Prostate-Specific Antigen-Based Prostate Cancer Screening Strategies. <i>Annals of Internal Medicine</i> , 2013, 158, 145.	2.0	144
575	The dilemmas of prostate cancer screening. <i>Medical Journal of Australia</i> , 2013, 198, 528-529.	0.8	4
576	Focal therapy for localized prostate cancer – choosing the middle ground. <i>Canadian Urological Association Journal</i> , 2013, 3, 333.	0.3	13
577	Cáncer de próstata y calidad de vida: análisis del cambio en la respuesta a partir de una triangulación entre métodos. <i>Psicooncología</i> , 2013, 9, .	0.1	1
578	Cancer estimates up to 2015 in Friuli Venezia Giulia. <i>Tumori</i> , 2013, 99, 318-326.	0.6	1
580	Factors influencing disease progression of prostate cancer under active surveillance: a multicenter cohort. <i>BJU International</i> , 2014, 114, E99-E104.	1.3	42
581	Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 157-162.	2.0	0
582	Kallikreins as Biomarkers for Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	43
583	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1387-1405.	1.2	117
584	Surgery versus observation for localized prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 312-313.	1.9	4
585	Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies. <i>International Journal of Urology</i> , 2014, 21, 786-792.	0.5	11
586	The prognostic significance of perineural invasion and race in men considering active surveillance. <i>BJU International</i> , 2014, 114, 75-80.	1.3	33

#	ARTICLE	IF	CITATIONS
587	Overdetection in screening for prostate cancer. <i>Current Opinion in Urology</i> , 2014, 24, 256-263.	0.9	36
588	Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men. <i>Pathology</i> , 2014, 46, 11-14.	0.3	8
589	Individualized Prostate-specific Antigen Threshold Values to Avoid Overdiagnosis of Prostate Cancer and Reduce Unnecessary Biopsy in Elderly Men. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 852-859.	0.6	1
590	Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?. <i>Genetics in Medicine</i> , 2014, 16, 338-346.	1.1	24
591	Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 217-223.	0.2	7
592	Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. <i>Cancer Causes and Control</i> , 2014, 25, 81-92.	0.8	192
593	Multiparametric MRI for prostate cancer detection: Performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 1206-1212.	1.9	21
595	Ensemble docking and molecular dynamics identify knoevenagel curcumin derivatives with potent anti-EGFR activity. <i>Gene</i> , 2014, 539, 82-90.	1.0	49
596	Overdiagnosis and Overtreatment of Prostate Cancer. <i>European Urology</i> , 2014, 65, 1046-1055.	0.9	709
597	Histopathological differences between prostate cancer foci that are detected and missed using multiparametric magnetic resonance imaging in Korean patients. <i>International Journal of Urology</i> , 2014, 21, 466-472.	0.5	4
598	Access, excess, and overdiagnosis: the case for thyroid cancer. <i>Cancer Medicine</i> , 2014, 3, 154-161.	1.3	52
599	The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men. <i>European Urology</i> , 2014, 66, 1109-1115.	0.9	74
600	Increased nuclear factor erythroid 2-related factor 2 expression predicts worse prognosis of prostate cancer patients treated with radical prostatectomy. <i>Human Pathology</i> , 2014, 45, 2211-2217.	1.1	4
601	PSA velocity: A systematic review of clinical applications. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1116-1125.	0.8	30
602	Focal therapy for prostate cancer. Alternative treatment. <i>Actas Urológicas Españolas (English Edition)</i> Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 1	0.2	3
603	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <i>Lancet, The</i> , 2014, 384, 2027-2035.	6.3	1,261
604	New concepts concerning prostate cancer screening. <i>Experimental Biology and Medicine</i> , 2014, 239, 793-804.	1.1	3
605	Active Surveillance for Low-risk Prostate Cancer in African American Men: Multi-institutional Experience. <i>Urology</i> , 2014, 83, 364-368.	0.5	39

#	ARTICLE	IF	CITATIONS
606	Terapia focal en c�ncer de pr�stata. Alternativas de tratamiento. Actas Urol�gicas Espa�olas, 2014, 38, 465-475.	0.3	8
607	Second Primary Cancers Occurring after I-125 Brachytherapy as Monotherapy for Early Prostate Cancer. Clinical Oncology, 2014, 26, 210-215.	0.6	17
608	Optimizaci�n de un programa de cribado oportunista de c�ncer de pr�stata; ensayo aleatorizado prospectivo del papel del PSA y del PCA3 en uso secuencial. Actas Urol�gicas Espa�olas, 2014, 38, 217-223.	0.3	10
609	Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer. Journal of Urology, 2014, 191, 629-637.	0.2	28
610	Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. British Journal of Cancer, 2014, 110, 2405-2411.	2.9	60
611	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	2.3	294
612	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. Annals of Internal Medicine, 2014, 161, 104.	2.0	123
614	In vivo <sup>1</sup> H/ <sup>1</sup> H MR spectroscopic imaging of aggressive prostate cancer: Can we detect lactate?. Magnetic Resonance in Medicine, 2014, 71, 26-34.	1.9	21
615	Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index. European Urology Focus, 2015, 1, 185-190.	1.6	23
616	Impact of Early Diagnosis of Prostate Cancer on Survival Outcomes. European Urology Focus, 2015, 1, 137-146.	1.6	18
617	Clinical significance of single microscopic focus of adenocarcinoma at prostate biopsy. Prostate International, 2015, 3, 132-134.	1.2	4
618	The ONCOTYROL Prostate Cancer Outcome and Policy Model. Medical Decision Making, 2015, 35, 758-772.	1.2	8
619	Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment. Health Expectations, 2015, 18, 3123-3135.	1.1	29
620	Mathematical models for diffusion-weighted imaging of prostate cancer using b values up to 2000 s/mm <sup>2</sup> : Correlation with Gleason score and repeatability of region of interest analysis. Magnetic Resonance in Medicine, 2015, 74, 1116-1124.	1.9	53
621	Prostate-specific antigen-based prostate cancer screening: Past and future. International Journal of Urology, 2015, 22, 524-532.	0.5	59
622	Comparison between Ultrasound Guided Transperineal and Transrectal Prostate Biopsy: A Prospective, Randomized and Controlled Trial. Scientific Reports, 2015, 5, 16089.	1.6	59
623	Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer. Scientific Reports, 2015, 5, 14045.	1.6	29
624	The Future of Prostate Cancer Diagnosis: Biomarkers, Biopsy, Both, or Neither?. European Urology Focus, 2015, 1, 97-98.	1.6	1

#	ARTICLE	IF	CITATIONS
625	Comparison of pathological data between prostate biopsy and radical prostatectomy specimen in patients with low to very low risk prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2015, 39, 482-487.	0.2	8
626	Observational studies and the natural history of screen-detected prostate cancer. <i>Current Opinion in Urology</i> , 2015, 25, 232-237.	0.9	54
627	Comparison of Pathological and Biochemical Outcomes after Radical Prostatectomy in Korean Patients with Serum PSA Ranges. <i>Journal of Korean Medical Science</i> , 2015, 30, 317.	1.1	3
628	The Risks and Benefits of Current Treatment Options for Prostate Cancer and Future Possibilities in Advanced Imaging and Targeted Therapy: A Review. <i>Archives of Surgical Oncology</i> , 2015, 01, .	0.1	0
629	L-amino acid transporter 1 may be a prognostic marker for local progression of prostatic cancer under expectant management. <i>Cancer Biomarkers</i> , 2015, 15, 365-374.	0.8	20
630	High Progesterone Receptor Expression in Prostate Cancer Is Associated with Clinical Failure. <i>PLoS ONE</i> , 2015, 10, e0116691.	1.1	42
631	Transabdominal Contrast-Enhanced Ultrasound Imaging of the Prostate. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 1112-1118.	0.7	8
632	Doctors' approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study. <i>BMJ Open</i> , 2015, 5, e006367-e006367.	0.8	33
633	Gama-glutamil trasferasa en suero, adyuvante del antígeno prostático específico en el diagnóstico del cáncer de próstata. <i>Revista Mexicana De Urologia</i> , 2015, 75, 325-331.	0.0	1
634	Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv345-djv345.	3.0	30
635	Has prostate cancer mortality stopped its decline in Spain?. <i>Actas Urológicas Españolas (English Edition)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.2	1
636	Economic evaluation of prostate cancer screening: a systematic review. <i>Future Oncology</i> , 2015, 11, 467-477.	1.1	9
637	Technical Aspects of Focal Therapy in Localized Prostate Cancer. , 2015, , .		10
638	Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. <i>Journal of the National Cancer Institute</i> , 2015, 107, 366.	3.0	120
639	The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen era. <i>International Journal of Cancer</i> , 2015, 137, 2795-2802.	2.3	204
640	Radical Prostatectomy Findings in Men on Active Surveillance: Variable Findings Dependent on Reason for Surgery and Entry Criteria. <i>Journal of Urology</i> , 2015, 194, 685-689.	0.2	3
641	Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme. <i>European Journal of Cancer</i> , 2015, 51, 1630-1637.	1.3	23
642	Screening for Prostate Cancer—Beyond Total PSA, Utilization of Novel Biomarkers. <i>Current Urology Reports</i> , 2015, 16, 63.	1.0	4

#	ARTICLE	IF	CITATIONS
643	National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. <i>Journal of Clinical Oncology</i> , 2015, 33, 2416-2423.	0.8	184
644	Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam. <i>European Urology</i> , 2015, 68, 179-182.	0.9	14
645	Patient-Reported Urinary Incontinence and Erectile Dysfunction Following Radical Prostatectomy: Results from the European Prostate Centre Innsbruck. <i>Urologia Internationalis</i> , 2015, 94, 419-427.	0.6	14
646	Comparación de datos anatomopatológicos entre biopsia de próstata y pieza de prostatectomía radical en pacientes con cáncer de bajo y muy bajo riesgo. <i>Actas Urológicas Españolas</i> , 2015, 39, 482-487.	0.3	9
647	Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. <i>European Urology</i> , 2015, 68, 805-811.	0.9	58
648	Guidance on Patient Consultation. Current Evidence for Prostate-Specific Antigen Screening in Healthy Men and Treatment Options for Men with Proven Localised Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 28.	1.0	1
649	Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 647-664.	1.5	40
650	Conditional Probability of Reclassification in an Active Surveillance Program for Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 1950-1955.	0.2	32
651	Is further screening of men with baseline PSA <math>\leq 1\text{ ng/ml}</math> worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau). <i>International Journal of Cancer</i> , 2015, 137, 553-559.	2.3	13
652	Criteria used for the active surveillance of localised prostate cancer in the UK. <i>Journal of Clinical Urology</i> , 2015, 8, 4-8.	0.1	0
653	Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. <i>European Urology</i> , 2015, 68, 756-765.	0.9	57
654	A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1864-1872.	1.1	13
655	Oncotryl - Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2015, 109, 330-340.	0.7	7
656	Ethnicity and prostate cancer: the way to solve the screening problem?. <i>BMC Medicine</i> , 2015, 13, 179.	2.3	5
657	Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. <i>British Journal of Cancer</i> , 2015, 113, 1086-1093.	2.9	32
658	¿Ha dejado de disminuir la mortalidad por cáncer de próstata en España?. <i>Actas Urológicas Españolas</i> , 2015, 39, 612-619.	0.3	4
659	Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 93-114.	0.8	36
660	A -PSA Pyramid for Men with Initial Prostate-specific Antigen $\geq 3\text{ ng/ml}$ : A Plea for Individualized Prostate Cancer Screening. <i>European Urology</i> , 2015, 68, 591-597.	0.9	26

#	ARTICLE	IF	CITATIONS
661	Advances in Image-Guided Urologic Surgery. , 2015, , .		3
662	Screening for prostate cancer in the US? Reduce the harms and keep the benefit. International Journal of Cancer, 2015, 136, 1600-1607.	2.3	22
663	Patterns of Care and Treatment Trends for Canadian Men with Localized Low-Risk Prostate Cancer: An Analysis of Provincial Cancer Registry Data. Current Oncology, 2016, 23, 56-59.	0.9	7
664	Current status of active surveillance in prostate cancer. Investigative and Clinical Urology, 2016, 57, 14.	1.0	22
665	Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies. Prostate Cancer, 2016, 2016, 1-7.	0.4	2
666	Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening. CMAJ Open, 2016, 4, E73-E79.	1.1	23
667	Sampling of the anterior apical region results in increased cancer detection and upgrading in transrectal repeat saturation biopsy of the prostate. BJU International, 2016, 117, 592-597.	1.3	21
668	A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (<scp>ERSPC</scp>, Aarau). BJU International, 2016, 117, 576-583.	1.3	36
669	Relaxation along fictitious field, diffusion-weighted imaging, and T<sub>2</sub> mapping of prostate cancer: Prediction of cancer aggressiveness. Magnetic Resonance in Medicine, 2016, 75, 2130-2140.	1.9	15
670	Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men. International Journal of Cancer, 2016, 138, 2522-2528.	2.3	6
671	Calibrating Parameters for Microsimulation Disease Models. Medical Decision Making, 2016, 36, 652-665.	1.2	9
672	Multiparametric MRI for prostate cancer detection: Preliminary results on quantitative analysis of dynamic contrast enhanced imaging, diffusion-weighted imaging and spectroscopy imaging. Magnetic Resonance Imaging, 2016, 34, 839-845.	1.0	21
673	Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review. Molecular Cancer, 2016, 15, 41.	7.9	76
674	The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index. Value in Health, 2016, 19, 153-157.	0.1	43
675	Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial. European Urology, 2016, 70, 760-766.	0.9	130
676	Interventions to encourage uptake of cancer screening for people with severe mental illness. The Cochrane Library, 2016, 2016, CD009641.	1.5	18
677	Limiting overdiagnosis of low-risk prostate cancer through an evaluation of the predictive value of transrectal and power Doppler ultrasonography. Journal of Ultrasound, 2016, 19, 275-280.	0.7	3
679	Development of a Microsimulation Model to Predict Stroke and Long-Term Mortality in Adherent and Nonadherent Medically Managed and Surgically Treated Octogenarians with Asymptomatic Significant Carotid Artery Stenosis. World Neurosurgery, 2016, 92, 513-520.e2.	0.7	4

#	ARTICLE	IF	CITATIONS
680	Consistent Bayesians Are No More Accurate Than Non-Bayesians: Economists Surveyed About PSA. <i>Review of Behavioral Economics</i> , 2016, 3, 189-219.	0.2	9
681	The percentage of prostate-specific antigen (PSA) isoform [p2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged 65 years. <i>BJU International</i> , 2016, 117, 72-79.	1.3	55
684	Differences in survival between Māori and New Zealand Europeans with prostate cancer. <i>European Journal of Cancer Care</i> , 2016, 25, 262-268.	0.7	4
685	Surface Enhanced Electrochemiluminescence Immunoassay for Highly Sensitive Detection of Disease Biomarkers in Whole Blood. <i>Electroanalysis</i> , 2016, 28, 1783-1786.	1.5	16
686	The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer. <i>Journal of Urology</i> , 2016, 195, 1390-1396.	0.2	20
687	Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve?. <i>Urology</i> , 2016, 93, 60-67.	0.5	11
688	4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening. <i>Urologic Clinics of North America</i> , 2016, 43, 39-46.	0.8	27
689	Prostate-Specific Antigen Screening Guidelines. , 2016, , 111-116.		3
690	Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 201-212.	1.2	13
691	Optimal scheduling of post-therapeutic follow-up of patients treated for cancer for early detection of relapses. <i>Statistical Methods in Medical Research</i> , 2016, 25, 2457-2471.	0.7	4
692	Fitting methods for intravoxel incoherent motion imaging of prostate cancer on region of interest level: Repeatability and gleason score prediction. <i>Magnetic Resonance in Medicine</i> , 2017, 77, 1249-1264.	1.9	48
693	Feasibility, acceptability and preliminary psychological benefits of mindfulness meditation training in a sample of men diagnosed with prostate cancer on active surveillance: results from a randomized controlled pilot trial. <i>Psycho-Oncology</i> , 2017, 26, 1155-1163.	1.0	46
694	Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study. <i>BJU International</i> , 2017, 119, 560-566.	1.3	13
695	Prostate Health Index density improves detection of clinically significant prostate cancer. <i>BJU International</i> , 2017, 120, 793-798.	1.3	69
696	Individual and Population-Based Screening. , 2017, , 43-55.		0
697	Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. <i>Clinical Cancer Research</i> , 2017, 23, 3823-3833.	3.2	43
698	A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. <i>BJU International</i> , 2017, 120, 774-781.	1.3	98
699	Is prostate cancer different in black men? Answers from 3 natural history models. <i>Cancer</i> , 2017, 123, 2312-2319.	2.0	100

#	ARTICLE	IF	CITATIONS
700	Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017. <i>Current Opinion in Urology</i> , 2017, 27, 198-204.	0.9	23
701	A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations. <i>Current Opinion in Urology</i> , 2017, 27, 475-480.	0.9	3
702	PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme. <i>Actas Urológicas Españolas (English Edition)</i> , 2017, 41, 300-308.	0.2	3
703	Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes. <i>International Urology and Nephrology</i> , 2017, 49, 1335-1342.	0.6	12
704	Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer. <i>Medical Decision Making</i> , 2017, 37, 815-826.	1.2	12
705	Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. <i>Scientific Reports</i> , 2017, 7, 738.	1.6	12
706	Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia. <i>Metabolomics</i> , 2017, 13, 52.	1.4	50
707	Breast, prostate, and thyroid cancer screening tests and overdiagnosis. <i>Current Problems in Cancer</i> , 2017, 41, 71-79.	1.0	14
708	Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA < 10 ng/ml. <i>Future Oncology</i> , 2017, 13, 1793-1800.	1.1	9
709	PET/CT in Prostate Cancer. , 2017, , .		0
710	PCA3 como biomarcador de segunda línea en un programa de screening oportunista prospectivo, aleatorizado y controlado. <i>Actas Urológicas Españolas</i> , 2017, 41, 300-308.	0.3	9
711	Retropubic Radical ProstatectomyRadical Prostatectomy. , 2017, , 231-249.		0
712	Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 664.e11-664.e18.	0.8	24
713	Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model. <i>BMC Public Health</i> , 2017, 17, 596.	1.2	12
715	Associations of Postdiagnosis Physical Activity and Change from Prediagnosis Physical Activity with Quality of Life in Prostate Cancer Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 179-187.	1.1	20
716	Cancer: Global Burden, Trends, and Projections. , 2017, , 347-368.		0
717	Researching the Research in Prostate Cancer: A Comparative Bibliometric Analysis of the Top 100 Cited Articles in the Field of Prostate Cancer. <i>Current Urology</i> , 2017, 11, 26-35.	0.4	8
718	Canadian Urological Association recommendations on prostate cancer screening and early diagnosis. <i>Canadian Urological Association Journal</i> , 2017, 11, 298-309.	0.3	55

#	ARTICLE	IF	CITATIONS
719	Update on Screening for Urological Malignancies. Rambam Maimonides Medical Journal, 2017, 8, e0041.	0.4	7
720	Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model. Frontiers in Oncology, 2017, 7, 290.	1.3	7
721	No change in the prevalence of latent prostate cancer over the last 10 years: a forensic autopsy study in Japan. Biomedical Research, 2017, 38, 307-312.	0.3	7
722	Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank. Biomarkers in Cancer, 2017, 9, 1179299X1771094.	3.6	9
724	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. JAMA - Journal of the American Medical Association, 2018, 319, 883.	3.8	296
725	Technique development of 3D dynamic CS&#x2013;PSI for hyperpolarized <sup>13</sup> C pyruvate MR molecular imaging of human prostate cancer. Magnetic Resonance in Medicine, 2018, 80, 2062-2072.	1.9	47
726	Estimating lead&#x2013;time bias in lung cancer diagnosis of patients with previous cancers. Statistics in Medicine, 2018, 37, 2516-2529.	0.8	8
727	Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study. Journal of Urology, 2018, 200, 82-88.	0.2	15
728	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
729	Summary statement on screening for prostate cancer in Europe. International Journal of Cancer, 2018, 142, 741-746.	2.3	29
730	Preoperative prostate health index predicts poor pathologic outcomes of radical prostatectomy in patients with biopsy-detected low-risk patients prostate cancer: results from a Chinese prospective cohort. Prostate Cancer and Prostatic Diseases, 2018, 21, 64-70.	2.0	5
731	Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance. Cancer, 2018, 124, 507-513.	2.0	6
732	Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU International, 2018, 121, 619-626.	1.3	70
733	Prostate cancer diagnosis and characterization with mass spectrometry imaging. Prostate Cancer and Prostatic Diseases, 2018, 21, 297-305.	2.0	19
734	Prospective Outcome Analysis of the Safety and Efficacy of Partial and Complete Cryoablation in Organ-confined Prostate Cancer. Urology, 2018, 112, 126-131.	0.5	16
735	Prostate cancer characteristics in the World Trade Center cohort, 2002&#x2013;2013. European Journal of Cancer Prevention, 2018, 27, 347-354.	0.6	17
736	Rastreamento populacional para o c�ncer de pr�stata: mais riscos que benef�cios. Physis, 2018, 28, .	0.1	4
737	Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts. British Journal of Cancer, 2018, 119, 1445-1450.	2.9	0

#	ARTICLE	IF	CITATIONS
739	A systematic approach for examining the impact of calibration uncertainty in disease modeling. <i>Computational Management Science</i> , 2018, 15, 541-561.	0.8	2
740	eHealth and mHealth in prostate cancer detection and active surveillance. <i>Translational Andrology and Urology</i> , 2018, 7, 170-181.	0.6	22
741	The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy. <i>Ecancermedicalsecience</i> , 2018, 12, 844.	0.6	2
742	Variability in the multicenter National Registry in Active Surveillance: a questionnaire for urologists. <i>Actas Urológicas Españolas (English Edition)</i> , 2018, 42, 442-449.	0.2	0
743	Social Network Based Big Data Analysis and Applications. <i>Lecture Notes in Social Networks</i> , 2018, , .	0.8	5
744	Variabilidad dentro del Registro Nacional multicéntrico en Vigilancia Activa; cuestionario a urólogos. <i>Actas Urológicas Españolas</i> , 2018, 42, 442-449.	0.3	6
745	Landmarks in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 627-642.	1.9	78
746	MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. <i>American Journal of Roentgenology</i> , 2018, 211, 595-604.	1.0	16
747	A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA. <i>Clinical Epigenetics</i> , 2018, 10, 91.	1.8	35
748	Prostate-Specific Antigen-Based Screening for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1914.	3.8	367
750	Can we expand the borders in active surveillance for low-risk prostate cancer?. <i>Journal of Clinical Urology</i> , 2019, 12, 54-59.	0.1	1
751	Systematic evaluation of written health information on PSA based screening in Germany. <i>PLoS ONE</i> , 2019, 14, e0220745.	1.1	2
752	Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization. <i>PLoS ONE</i> , 2019, 14, e0217702.	1.1	76
753	<sup>18</sup> F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1705-1712.	2.8	12
754	Microsimulation Model Using Christiana Care Early Warning System (CEWS) to Evaluate Physiological Deterioration. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2019, 23, 2189-2195.	3.9	1
755	Abbreviated Magnetic Resonance Imaging (MRI) for Breast Cancer Screening: Rationale, Concept, and Transfer to Clinical Practice. <i>Annual Review of Medicine</i> , 2019, 70, 501-519.	5.0	92
756	Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?. <i>PLoS ONE</i> , 2019, 14, e0210434.	1.1	11
757	Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach. <i>BMJ Open</i> , 2019, 9, e022457.	0.8	24

#	ARTICLE	IF	CITATIONS
758	An electrochemical sarcosine sensor based on biomimetic recognition. <i>Mikrochimica Acta</i> , 2019, 186, 136.	2.5	14
759	A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. <i>PLoS ONE</i> , 2019, 14, e0211918.	1.1	10
760	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. <i>European Urology</i> , 2019, 76, 43-51.	0.9	359
761	Performance and inter-observer variability of prostate MRI (PI-RADS version 2) outside high-volume centres. <i>Scandinavian Journal of Urology</i> , 2019, 53, 304-311.	0.6	31
762	The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 137-142.	2.0	20
763	Defining clinically significant prostate cancer on the basis of pathological findings. <i>Histopathology</i> , 2019, 74, 135-145.	1.6	114
764	Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. <i>Cancer</i> , 2019, 125, 550-558.	2.0	6
765	Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A Review. <i>Oncologist</i> , 2019, 24, 375-384.	1.9	22
766	Comparing signal-to-noise ratio for prostate imaging at 7T and 3T. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 1446-1455.	1.9	19
767	Regulation of PDE 5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. <i>Andrology</i> , 2020, 8, 427-433.	1.9	5
768	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. <i>European Urology</i> , 2020, 77, 24-35.	0.9	124
769	Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of Diet and Cancer. <i>Annals of Oncology</i> , 2020, 31, 103-114.	0.6	35
770	Hormone-related diseases and prostate cancer: An English national record linkage study. <i>International Journal of Cancer</i> , 2020, 147, 803-810.	2.3	21
771	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. <i>Cancer</i> , 2020, 126, 717-724.	2.0	64
772	Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer. <i>Clinica Chimica Acta</i> , 2020, 501, 174-178.	0.5	11
773	Estimating the magnitude of cancer overdiagnosis in Australia. <i>Medical Journal of Australia</i> , 2020, 212, 163-168.	0.8	92
774	The importance of PSA-Density in active surveillance for prostate cancer. <i>Archivio Italiano Di Urologia Andrologia</i> , 2020, 92, .	0.4	7
775	Changing Provider PSA Screening Behavior Using Best Practice Advisories: Interventional Study in a Multispecialty Group Practice. <i>Journal of General Internal Medicine</i> , 2020, 35, 796-801.	1.3	2

#	ARTICLE	IF	CITATIONS
776	Personalized strategies in population screening for prostate cancer. <i>International Journal of Cancer</i> , 2020, 147, 2977-2987.	2.3	19
777	Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review. <i>Oncology Reviews</i> , 2020, 14, 449.	0.8	5
778	&lt;p&gt;Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 5225-5241.	0.9	25
779	Long-term Trends in Prostate Cancer Incidence by Stage at Diagnosis in Japan Using the Multiple Imputation Approach, 1993â€“2014. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1222-1228.	1.1	13
780	A discussion on controversies and ethical dilemmas in prostate cancer screening. <i>Journal of Medical Ethics</i> , 2021, 47, 152-158.	1.0	11
782	Simulation model of disease incidence driven by diagnostic activity. <i>Statistics in Medicine</i> , 2021, 40, 1172-1188.	0.8	4
783	Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study. <i>BMC Public Health</i> , 2021, 21, 23.	1.2	2
784	Overdiagnosis in urologic cancer. <i>World Journal of Urology</i> , 2022, 40, 1-8.	1.2	14
785	The Role of E-Health Interventions in Improving Clinical Outcomes and Overall Health for Prostate Cancer Patients. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2021, , 144-171.	0.3	0
786	The GÃ–TEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. <i>Scandinavian Journal of Urology</i> , 2021, 55, 116-124.	0.6	27
787	Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance. <i>Diagnostics</i> , 2021, 11, 355.	1.3	12
788	Prostate cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 9.	18.1	434
789	Identifying key factors for the effectiveness of pancreatic cancer screening: A modelâ€“based analysis. <i>International Journal of Cancer</i> , 2021, 149, 337-346.	2.3	8
791	Prognostic Value of BRCA1 and BRCA2 Gene Mutations in Prostate Cancer: a Literature Review. <i>KreativnaÃ“ HirurgiÃ“ I OnkologiÃ“</i> , 2021, 11, 183-187.	0.1	1
792	Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey. <i>Urologia Internationalis</i> , 2021, , 1-9.	0.6	0
793	Plasma Metabolomics for Discovery of Early Metabolic Markers of Prostate Cancer Based on Ultra-High-Performance Liquid Chromatography-High Resolution Mass Spectrometry. <i>Cancers</i> , 2021, 13, 3140.	1.7	10
794	Diagnostic algorithms in prostate cancer - 1<sup>st</sup> part. <i>Urologie Pro Praxi</i> , 2021, 22, 88-91.	0.0	0
795	Genetic polymorphisms at 19q13.33 are associated with [âˆ²]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer. <i>Prostate</i> , 2021, 81, 971-982.	1.2	4

#	ARTICLE	IF	CITATIONS
796	The role of targeted biopsy methods in the prostate cancer diagnosis. <i>Onkourologiya</i> , 2021, 17, 157-167.	0.1	0
797	Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study. <i>European Urology Open Science</i> , 2021, 29, 30-35.	0.2	2
798	Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017. <i>Prostate</i> , 2021, 81, 1071-1077.	1.2	8
799	Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 4251.	1.7	17
800	Germline Testing for Prostate Cancer Prognosis. <i>Urologic Clinics of North America</i> , 2021, 48, 401-409.	0.8	4
801	Multicancer Early Detection: Learning From the Past to Meet the Future. <i>Journal of the National Cancer Institute</i> , 2022, 114, 349-352.	3.0	22
802	The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. <i>BJU International</i> , 2022, 129, 325-336.	1.3	15
803	Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial. <i>European Urology Oncology</i> , 2022, 5, 54-60.	2.6	12
804	Discontinuing Cancer Screening for Older Adults: a Comparison of Clinician Decision-Making for Breast, Colorectal, and Prostate Cancer Screenings. <i>Journal of General Internal Medicine</i> , 2022, 37, 1122-1128.	1.3	8
807	Cancer Screenings, Diagnostic Technology Evolution, and Cancer Control. <i>Methods in Molecular Biology</i> , 2009, 471, 107-136.	0.4	7
808	Overview of US Prostate Cancer Trends in the Era of PSA Screening. , 2009, , 3-14.		3
809	Trends in Prostate Cancer Screening: Overview of the UK. , 2009, , 15-21.		4
810	Trends in Prostate Cancer Screening - Overview of Europe. , 2009, , 35-47.		1
811	Active Surveillance and Focal Therapy: A European Perspective. , 2013, , 37-52.		1
812	Cancer Overdiagnosis and Overtreatment. <i>Current Clinical Urology</i> , 2018, , 1-8.	0.0	2
813	Prognostic Factors in Prostate Cancer. , 2007, 175, 25-32.		10
815	Definitive Therapy for Localized Prostate Cancer. , 2012, , 2771-2788.e6.		2
816	What we have learned from randomized trials of prostate cancer screening. <i>Asian Journal of Andrology</i> , 2011, 13, 369-373.	0.8	5

#	ARTICLE	IF	CITATIONS
817	Updated results from the European Randomized Study of Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: are Asian countries encouraged to promote PSA screening?. Asian Journal of Andrology, 2012, 14, 522-524.	0.8	5
818	Associations among statins, preventive care, and prostate cancer mortality. Prostate Cancer and Prostatic Diseases, 2020, 23, 475-485.	2.0	9
819	Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. Journal of Urology, 2020, 204, 281-288.	0.2	19
820	Reliability of PSA testing remains unclear. BMJ: British Medical Journal, 2003, 327, 750-750.	2.4	7
821	Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight, 2018, 3, .	2.3	71
822	The evolving biology and treatment of prostate cancer. Journal of Clinical Investigation, 2007, 117, 2351-2361.	3.9	119
823	RNA-guided diagnostics and therapeutics for next-generation individualized nanomedicine. Journal of Clinical Investigation, 2013, 123, 2350-2352.	3.9	7
824	Active Surveillance of Prostate Cancer Using Multiparametric Magnetic Resonance Imaging: A Review of the Current Role and Future Perspectives. Medical Science Monitor, 2020, 26, e920252.	0.5	16
825	Macrophage Inhibitory Cytokine 1 Biomarker Serum Immunoassay in Combination with PSA Is a More Specific Diagnostic Tool for Detection of Prostate Cancer. PLoS ONE, 2015, 10, e0122249.	1.1	22
826	The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening. PLoS ONE, 2016, 11, e0152999.	1.1	15
827	Screening for Prostate Cancer with Prostate-Specific Antigen: What's the Evidence?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 96-100.	1.8	5
828	The Mind. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 10-14.	0.7	8
830	Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancer. Oncotarget, 2017, 8, 17862-17872.	0.8	20
831	Lead-time bias in esophageal cancer screening in high-risk areas in China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 467-475.	0.7	2
832	Does Consistency Predict Accuracy of Beliefs?: Economists Surveyed About PSA. SSRN Electronic Journal, 0, , .	0.4	7
833	Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technology Assessment, 2009, 13, iii, xi-xiii 1-219.	1.3	103
834	Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy. Ecancermedicallscience, 2019, 13, 934.	0.6	12
835	Recent advances in magnetic resonance imaging of prostate cancer. F1000 Medicine Reports, 2010, 2, 86.	2.9	3

#	ARTICLE	IF	CITATIONS
837	Prostate Cancer and Quality of Life: Analysis of Response Shift Using Triangulation Between Methods. Journal of Gerontological Nursing, 2014, 40, 32-41.	0.3	4
838	Prostate-specific antigen: how to advise patients as the screening debate continues.. Cleveland Clinic Journal of Medicine, 2005, 72, 521-527.	0.6	5
839	Changes in pathologic outcomes and operative trends with robot-assisted laparoscopic radical prostatectomy. Indian Journal of Urology, 2014, 30, 378.	0.2	6
840	The routine use of prostate-specific antigen for early detection of cancer prostate in India: Is it justified?. Indian Journal of Urology, 2009, 25, 177.	0.2	11
841	Prostate volume does not provide additional predictive value to prostate health index for prostate cancer or clinically significant prostate cancer: results from a multicenter study in China. Asian Journal of Andrology, 2020, 22, 539.	0.8	7
842	Role of serial multiparametric magnetic resonance imaging in prostate cancer active surveillance. World Journal of Radiology, 2016, 8, 410.	0.5	12
843	How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome. Turkish Journal of Urology, 2017, 43, 456-461.	1.3	3
844	PSA doubling time as a predictor of the outcome of random prostate biopsies prompted by isolated PSA elevation in subjects referred to an outpatient biopsy facility in a routine clinical scenario. International Journal of Biological Markers, 2008, 23, 187-191.	0.7	2
845	On the clinical usefulness of the free-to-total prostate-specific antigen ratio. International Journal of Biological Markers, 2006, 21, 1-5.	0.7	2
846	Role for <sup>11</sup> C-choline PET in active surveillance of prostate cancer. Canadian Urological Association Journal, 2015, 9, 98.	0.3	2
847	Extended use of P504S Positive Primary Circulating Prostate Cell Detection to Determine the Need for Initial Prostate Biopsy in a Prostate Cancer Screening Program in Chile. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9335-9339.	0.5	6
848	Prostate Cancer and Asbestos: A Systematic Review and Meta-Analysis. , 2020, 24, .		14
849	Genitourinary malignancies. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 485-513.	0.5	0
850	Active Surveillance with Selective Delayed Intervention for Favorable Risk Prostate Cancer. Seminars in Preventive and Alternative Medicine, 2006, 2, 15-21.	0.1	2
851	The Economic Impact of Prostate Cancer Screening and Treatment. North Carolina Medical Journal, 2006, 67, 158-160.	0.1	1
853	Epidemiology, Pathology and Pathogenesis. , 2008, , 451-469.		13
854	PSA Velocity at Presentation as a Predictor of Prostate Cancer Aggressiveness. , 2009, , 97-113.		0
855	The European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2009, , 373-386.		0

#	ARTICLE	IF	CITATIONS
856	Prostate-specific antigen and unwarranted use of costly investigations in medical practice. Galle Medical Journal, 2009, 12, 31.	0.1	0
857	What Are Some New Developments in Prostate Cancer Diagnosis?. Journal of the Korean Medical Association, 2010, 53, 107.	0.1	0
858	Diagnosis of Lung Cancer â€” Improving Survival Rates. European Oncology and Haematology, 2010, 06, 26.	0.0	0
859	Controversies in Prostate Cancer. , 2010, , 229-250.		2
864	Patient Selection for Active Surveillance. , 2012, , 9-21.		0
865	Active Surveillance: The European Experience. , 2012, , 81-94.		0
866	Urologistsâ€™ Opinion on Active Surveillance: USA Versus the Netherlands. , 2012, , 157-168.		0
869	Urologic Oncology. , 2013, , 95-123.		0
872	Prostate Carcinoma Surveillance Counterpoint: Europe. , 2013, , 421-422.		0
874	Prostate Cancer Treatment on the Basis of an Individual Risk Profile; Can we Reduce Overtreatment?. Journal of Analytical Oncology, 0, , .	0.1	0
875	Prostate Cancer in Older Adults. , 2014, , 273-288.		0
876	Prostatokarzinom. , 2014, , 513-676.		0
877	Going Beyond Hair: Seven Simple Actions We Can Take to Help Prevent Major Illness in Our Hair Transplant Patients. International Society of Hair Restoration Surgery, 2014, 24, 54-56.	0.1	0
879	Expectant Management of Localized Prostate Cancer. , 2015, , 719-730.		0
881	EinfÃ¼hrung in die geriatrische Urologie. , 2015, , 1-10.		0
882	Nothing like data showing significant death reduction can better support prostate cancer screening. World Journal of Clinical Urology, 2015, 4, 97.	0.0	0
883	Prostatos vÃ¡rtiklos skaiuoklÃ¡s galimybiÅ³ vertinimas planuojant prostatos biopsijÃ¡... Medicinos Teorija Ir Praktika, 2015, 21, 277-279.	0.0	0
884	Oncologic Outcomes after Radical Retropubic Prostatectomy in Patients Meeting the Epstein Criteria. Journal of Academic Research in Medicine, 2015, 5, 6-9.	0.1	0

#	ARTICLE	IF	CITATIONS
885	Population Screening for Prostate Cancer and Early Detection. , 2016, , 3-12.		0
886	Decision Support for Low-Risk Prostate Cancer. , 2016, , 207-213.		1
887	Should Gleason Score 6 Still Be Called Cancer?. , 2016, , 41-47.		0
888	Quality of life in a population of Polish patients with prostate cancer. Central European Journal of Urology, 2016, 69, 53-6.	0.2	2
889	The Role of Microsimulation Modeling in Evaluating the Outcomes and Effect of Screening. , 2016, , 103-132.		0
890	Urologic Oncology. , 2016, , 77-107.		0
891	Einführung in die geriatrische Urologie. , 2016, , 2253-2259.		2
893	Natural History of Untreated Localized Prostate Cancer: Rational for Active Surveillance. , 2017, , 1-11.		0
894	Utilizing Biopsy-Based Genomic Assays to Risk-Stratify Patients. Current Clinical Urology, 2017, , 115-128.	0.0	0
895	Management of Prostate Cancer. , 2017, , 19-26.		0
896	Triggers for Intervention. Current Clinical Urology, 2018, , 83-94.	0.0	0
897	Timelines of Prostate Cancer Biomarkers. Lecture Notes in Social Networks, 2018, , 105-121.	0.8	0
899	Natural History of Untreated Localized Prostate Cancer: Rational for Active Surveillance. , 2019, , 179-190.		0
900	PSA screening - for whom and when?. Asian Journal of Andrology, 2019, 21, 3.	0.8	0
901	Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2020, 41, 5-14.	0.2	0
902	Some characteristics of patients with myelodysplastic syndrome. Medical Herald of the South of Russia, 2020, 11, 32-42.	0.2	0
903	Accuracy of Diagnosis with Non-contrast Magnetic Resonance Imaging/Transrectal Ultrasound Fusion-Guided Transperineal Prostate Biopsy. Juntendo Medical Journal, 2020, 66, 46-51.	0.1	0
905	Staging of Prostate Cancer. , 2007, 175, 109-130.		0

#	ARTICLE	IF	CITATIONS
906	Prostatakarzinom. , 2014, , 513-676.		0
908	Twenty Years of PSA: From Prostate Antigen to Tumor Marker. <i>Reviews in Urology</i> , 2007, 9, 113-23.	0.9	60
910	Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. <i>Reviews in Urology</i> , 2009, 11, 127-33.	0.9	50
911	Use of the prostate-specific antigen test among men aged 75 years or older in the United States: 2006 Behavioral Risk Factor Surveillance System. <i>Preventing Chronic Disease</i> , 2010, 7, A84.	1.7	9
912	Screening for prostate cancer: a controversy or fact. <i>Hippokratia</i> , 2010, 14, 170-5.	0.3	7
913	A review of focal therapy techniques in prostate cancer: clinical results for high-intensity focused ultrasound and focal cryoablation. <i>Reviews in Urology</i> , 2011, 13, e196-202.	0.9	6
914	Active surveillance for prostate cancer: a legal perspective. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 323-31.	0.4	0
915	Treatment of localized prostate cancer in elderly patients. <i>Gland Surgery</i> , 2015, 4, 283-7.	0.5	0
917	Highly portable quantitative screening test for prostate-specific antigen at point of care. <i>Current Research in Biotechnology</i> , 2021, 3, 288-299.	1.9	12
918	Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis. <i>Cancer Epidemiology</i> , 2022, 77, 102093.	0.8	13
919	Protein signatures to distinguish aggressive from indolent prostate cancer. <i>Prostate</i> , 2022, 82, 605-616.	1.2	10
920	The role of MRI in prostate cancer: current and future directions. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2022, 35, 503-521.	1.1	7
921	UPDATE “ 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2021, 16, E184-96.	0.3	12
922	Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 592-599.	3.0	5
923	Prognostic values of the core components of the mammalian circadian clock in prostate cancer. <i>PeerJ</i> , 2021, 9, e12539.	0.9	3
924	Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature. <i>Contrast Media and Molecular Imaging</i> , 2021, 2021, 1-10.	0.4	10
926	Optimization of Biomarker-Based Prostate Cancer Screening Policies. , 2022, , 141-158.		0
928	The European Randomized Study of Screening for Prostate Cancer (ERSPC). , 0, , 291-310.		0

#	ARTICLE	IF	CITATIONS
929	The Role of Conservative Policies in the Treatment of Prostate Cancer. , 0, , 153-166.		0
930	Cancer estimates up to 2015 in Friuli Venezia Giulia. Tumori, 2013, 99, 318-26.	0.6	0
932	PSA: role in screening and monitoring patients with prostate cancer. , 2022, , 131-172.		2
933	Cancer overdiagnosis: A challenge in the era of screening. Journal of the National Cancer Center, 2022, 2, 235-242.	3.0	14
934	Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans. JAMA Oncology, 2022, 8, 1471.	3.4	4
935	Einführung in die geriatrische Urologie. Springer Reference Medizin, 2022, , 1-7.	0.0	0
936	Analyzing Factors Enabling Prostate Cancer Screening Behaviors Among African American Males in the South Region Using the Andersen's Behavioral Model of Healthcare Services Utilization. , 0, , .		1
937	Comparison of Outcomes of Active Surveillance in Intermediate-Risk Versus Low-Risk Localised Prostate Cancer Patients: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 2732.	1.0	3
938	Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer. Cancers, 2023, 15, 1621.	1.7	8
939	Low-Value Prostate-Specific Antigen Screening in Older Males. JAMA Network Open, 2023, 6, e237504.	2.8	6
943	Einführung in die geriatrische Urologie. Springer Reference Medizin, 2023, , 2629-2635.	0.0	0